General Principles and a Phenomenology-Based Approach to Movement Disorders and Inherited Metabolic Disorders

Garrod, AE. The incidence of alkaptonuria: A study in chemical individuality. Lancet. 1902;2:1616–20.Google Scholar

Garrod, AE. The Croonian lectures on inborn errors of metabolism. Lancet. 1908;2:1–7.Google Scholar

Ferreira, CR, van Karnebeek, CDM, Vockley, J, Blau, N. A proposed nosology of inborn errors of metabolism. Genet Med. 2019;21(1):102–6.CrossRef Google Scholar

Ebrahimi-Fakhari, D, Saffari, A, Wahlster, L, et al. Congenital disorders of autophagy: An emerging novel class of inborn errors of neuro-metabolism. Brain. 2016;139(Pt 2):317–37.CrossRef Google Scholar PubMed

Ebrahimi-Fakhari, D, Van Karnebeek, C, Munchau, A. Movement disorders in treatable inborn errors of metabolism. Mov Disord. 2019;34:598–613.Google Scholar

Patterson, MC, Mengel, E, Wijburg, FA, et al. Disease and patient characteristics in NP-C patients: Findings from an international disease registry. Orphanet J Rare Dis. 2013;8:12.Google Scholar

Stampfer, M, Theiss, S, Amraoui, Y, et al. Niemann–Pick disease type C clinical database: Cognitive and coordination deficits are early disease indicators. Orphanet J Rare Dis. 2013;8:35.CrossRef Google Scholar PubMed

Carstea, ED, Morris, JA, Coleman, KG, et al. Niemann–Pick C1 disease gene: Homology to mediators of cholesterol homeostasis. Science. 1997;277(5323):228-31.Google Scholar

Naureckiene, S, Sleat, DE, Lackland, H, et al. Identification of HE1 as the second gene of Niemann–Pick C disease. Science. 2000;290(5500):2298–301.CrossRef Google Scholar PubMed

Anheim, M, Lagha-Boukbiza, O, Fleury-Lesaunier, MC, et al. Heterogeneity and frequency of movement disorders in juvenile and adult-onset Niemann–Pick C disease. J Neurol. 2014;261(1):174–9.CrossRef Google Scholar PubMed

Ebrahimi-Fakhari, D, Hildebrandt, C, Davis, PE, et al. The spectrum of movement disorders in childhood-onset lysosomal storage diseases. Mov Disord Clin Pract. 2018;5(2):149–55.CrossRef Google Scholar PubMed

Sevin, M, Lesca, G, Baumann, N, Millat, G, Lyon-Caen, O, Vanier, MT, et al. The adult form of Niemann–Pick disease type C. Brain. 2007;130(Pt 1):120–33.Google Scholar

Koens, LH, Kuiper, A, Coenen, MA, et al. Ataxia, dystonia and myoclonus in adult patients with Niemann–Pick type C. Orphanet J Rare Dis. 2016;11:121.Google Scholar

Patterson, MC, Clayton, P, Gissen, P, et al. Recommendations for the detection and diagnosis of Niemann–Pick disease type C: An update. Neurol Clin Pract. 2017;7(6):499–511.CrossRef Google Scholar PubMed

Synofzik, M, Harmuth, F, Stampfer, M, et al. NPC1 is enriched in unexplained early onset ataxia: A targeted high-throughput screening. J Neurol. 2015;262(11):2557–63.CrossRef Google Scholar PubMed

Synofzik, M, Fleszar, Z, Schols, L, et al. Identifying Niemann-Pick type C in early-onset ataxia: two quick clinical screening tools. J Neurol. 2016;263(10):1911-8.Google Scholar

Canafoglia, L, Bugiani, M, Uziel, G, et al. Rhythmic cortical myoclonus in Niemann–Pick disease type C. Mov Disord. 2006;21(9):1453–6.Google Scholar

Pineda, M, Mengel, E, Jahnova, H, et al. A suspicion index to aid screening of early-onset Niemann–Pick disease type C (NP-C). BMC Pediatrics. 2016;16:107.CrossRef Google Scholar PubMed

Patterson, MC, Hendriksz, CJ, Walterfang, M, et al. Recommendations for the diagnosis and management of Niemann–Pick disease type C: An update. Mol Genet Metab. 2012;106(3):330–44.Google Scholar

Ory, DS, Ottinger, EA, Farhat, NY, et al. Intrathecal 2-hydroxypropyl-beta-cyclodextrin decreases neurological disease progression in Niemann–Pick disease, type C1: A non-randomised, open-label, phase 1-2 trial. Lancet. 2017;390(10104):1758–68.Google Scholar

Tuschl, K, Clayton, PT, Gospe, SM, Jr., et al. Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man. Am J Hum Genet. 2012;90(3):457–66.Google Scholar

Quadri, M, Federico, A, Zhao, T, et al. Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. Am J Hum Genet. 2012;90(3):467–77.Google Scholar

Tuschl, K, Mills, PB, Parsons, H, et al. Hepatic cirrhosis, dystonia, polycythaemia and hypermanganesaemia: A new metabolic disorder. J Inherit Metab Dis. 2008;31(2):151–63.CrossRef Google Scholar PubMed

Gospe, SM, Jr., Caruso, RD, Clegg, MS, et al. Paraparesis, hypermanganesaemia, and polycythaemia: A novel presentation of cirrhosis. Arch Dis Child. 2000;83(5):439–42.Google Scholar

Brna, P, Gordon, K, Dooley, JM, Price, V. Manganese toxicity in a child with iron deficiency and polycythemia. J Child Neurol. 2011;26(7):891–4.Google Scholar

Quadri, M, Kamate, M, Sharma, S, et al. Manganese transport disorder: Novel SLC30A10 mutations and early phenotypes. Mov Disord. 2015;30(7):996–1001.CrossRef Google Scholar PubMed

Zaki, MS, Issa, MY, Elbendary, HM, et al. Hypermanganesemia with dystonia, polycythemia and cirrhosis in 10 patients: Six novel SLC30A10 mutations and further phenotype delineation. Clin Genet. 2018; 93(4):905–12.CrossRef Google Scholar PubMed

Tuschl, K, Meyer, E, Valdivia, LE, et al. Mutations in SLC39A14 disrupt manganese homeostasis and cause childhood-onset parkinsonism–dystonia. Nature Commun. 2016;7:11601.Google Scholar

Aydemir, TB, Kim, MH, Kim, J, et al. Metal Transporter Zip14 (SlC39A14) deletion in mice increases manganese deposition and produces neurotoxic signatures and diminished motor activity. J Neurosci. 2017;37(25):5996–6006.Google Scholar

Jenkitkasemwong, S, Akinyode, A, Paulus, E, et al. SLC39A14 deficiency alters manganese homeostasis and excretion resulting in brain manganese accumulation and motor deficits in mice. Proc Natl Acad Sci USA. 2018;115(8):E1769–78.CrossRef Google Scholar PubMed

Xin, Y, Gao, H, Wang, J, et al. Manganese transporter SlC39A14 deficiency revealed its key role in maintaining manganese homeostasis in mice. Cell Discov. 2017;3:17025.Google Scholar

Rodan, LH, Hauptman, M, D’Gama, AMet al. Novel founder intronic variant in SLC39A14 in two families causing manganism and potential treatment strategies. Mol Genet Metab. 2018;124(2):161–7.Google Scholar

Stamelou, M, Tuschl, K, Chong, WK, et al. Dystonia with brain manganese accumulation resulting from SLC30A10 mutations: A new treatable disorder. Mov Disord. 2012;27(10):1317–22.Google Scholar

Di Toro Mammarella, L, Mignarri, A, Battisti, C, et al. Two-year follow-up after chelating therapy in a patient with adult-onset parkinsonism and hypermanganesaemia due to SLC30A10 mutations. J Neurol. 2014;261(1):227–8.Google Scholar

Gulab, S, Kayyali, HR, Al-Said, Y. Atypical neurologic phenotype and novel SLC30A10 mutation in two brothers with hereditary hypermanganesemia. Neuropediatrics. 2018;49(1):72–5.Google Scholar

Marti-Sanchez, L, Ortigoza-Escobar, JD, Darling, A, et al. Hypermanganesemia due to mutations in SLC39A14: Further insights into Mn deposition in the central nervous system. Orphanet J Rare Dis. 2018;13:28.Google Scholar

Mukhtiar, K, Ibrahim, S, Tuschl, K, Mills, P. Hypermanganesemia with dystonia, polycythemia and cirrhosis (HMDPC) due to mutation in the SLC30A10 gene. Brain Dev. 2016;38(9):862–5.Google Scholar

Cali, JJ, Hsieh, CL, Francke, U, Russell, DW. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem. 1991;266(12):7779–83.CrossRef Google Scholar PubMed

Wong, JC, Walsh, K, Hayden, D, Eichler, FS. Natural history of neurological abnormalities in cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2018;41(4):647–56.CrossRef Google Scholar PubMed

Degos, B, Nadjar, Y, Amador Mdel, M, et al. Natural history of cerebrotendinous xanthomatosis: A paediatric disease diagnosed in adulthood. Orphanet J Rare Dis. 2016;11:41.Google Scholar

Lagarde, J, Roze, E, Apartis, E, et al. Myoclonus and dystonia in cerebrotendinous xanthomatosis. Mov Disord. 2012;27(14):1805–10.Google Scholar

Rubio-Agusti, I, Kojovic, M, Edwards, MJ, et al. Atypical parkinsonism and cerebrotendinous xanthomatosis: Report of a family with corticobasal syndrome and a literature review. Mov Disord. 2012;27(14):1769–74.Google Scholar

Mignarri, A, Dotti, MT, Federico, A, et al. The spectrum of magnetic resonance findings in cerebrotendinous xanthomatosis: Redefinition and evidence of new markers of disease progression. J Neurol. 2017;264(5):862–74.Google Scholar

Berginer, VM, Gross, B, Morad, K, et al. Chronic diarrhea and juvenile cataracts: Think cerebrotendinous xanthomatosis and treat. Pediatrics. 2009;123(1):143–7.Google Scholar

Biery, BJ, Stein, DE, Morton, DH, Goodman, SI. Gene structure and mutations of glutaryl-coenzyme A dehydrogenase: impaired association of enzyme subunits that is due to an A421V substitution causes glutaric acidemia type I in the Amish. Am J Hum Genet. 1996;59(5):1006–11.Google Scholar

Kolker, S, Burgard, P, Sauer, SW, Okun, JG. Current concepts in organic acidurias: Understanding intra- and extracerebral disease manifestation. J Inherit Metab Dis. 2013;36(4):635-44.Google Scholar

Kolker, S, Garcia-Cazorla, A, Valayannopoulos, V, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: The initial presentation. J Inherit Metab Dis. 2015;38(6):1041–57.Google Scholar

Gitiaux, C, Roze, E, Kinugawa, K, et al. Spectrum of movement disorders associated with glutaric aciduria type 1: A study of 16 patients. Mov Disord. 2008;23(16):2392–7.Google Scholar

Kulkens, S, Harting, I, Sauer, S, et al. Late-onset neurologic disease in glutaryl-CoA dehydrogenase deficiency. Neurology. 2005;64(12):2142–4.Google Scholar

Kolker, S, Valayannopoulos, V, Burlina, AB, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: The evolving clinical phenotype. J Inherit Metab Dis. 2015;38(6):1059–74.Google Scholar

Harting, I, Neumaier-Probst, E, Seitz, A, et al. Dynamic changes of striatal and extrastriatal abnormalities in glutaric aciduria type I. Brain. 2009;132(Pt 7):1764–82.Google Scholar

Heringer, J, Boy, SP, Ensenauer, R, et al. Use of guidelines improves the neurological outcome in glutaric aciduria type I. Ann Neurol. 2010;68(5):743–52.CrossRef Google Scholar PubMed

Boy, N, Muhlhausen, C, Maier, EM, et al. Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: Second revision. J Inherit Metab Dis. 2017;40(1):75–101.Google Scholar

Strauss, KA, Brumbaugh, J, Duffy, A, et al. Safety, efficacy and physiological actions of a lysine-free, arginine-rich formula to treat glutaryl-CoA dehydrogenase deficiency: Focus on cerebral amino acid influx. Mol Genet Metab. 2011;104(1-2):93–106.Google Scholar

Mercimek-Mahmutoglu, S, Stoeckler-Ipsiroglu, S, Adami, A, et al. GAMT deficiency: Features, treatment, and outcome in an inborn error of creatine synthesis. Neurology. 2006;67(3):480–4.Google Scholar

Salomons, GS, van Dooren, SJ, Verhoeven, NM, et al. X-linked creatine-transporter gene (SLC6A8) defect: A new creatine-deficiency syndrome. Am J Hum Genet. 2001;68(6):1497–500.CrossRef Google Scholar PubMed

Khaikin, Y, Sidky, S, Abdenur, J, et al. Treatment outcome of twenty-two patients with guanidinoacetate methyltransferase deficiency: An international retrospective cohort study. Eur J Paed Neurol. 2018;22(3):369–79.Google Scholar

O’Rourke, DJ, Ryan, S, Salomons, G, et al. Guanidinoacetate methyltransferase (GAMT) deficiency: Late onset of movement disorder and preserved expressive language. Dev Med Child Neurol. 2009;51(5):404–7.Google Scholar

van de Kamp, JM, Betsalel, OT, Mercimek-Mahmutoglu, S, et al. Phenotype and genotype in 101 males with X-linked creatine transporter deficiency. J Med Genet. 2013;50(7):463–72.Google Scholar

Ozand, PT, Gascon, GG, Al Essa, M, et al. Biotin-responsive basal ganglia disease: A novel entity. Brain. 1998;121(Pt 7):1267–79.Google Scholar

Zeng, WQ, Al-Yamani, E, Acierno, JS, Jr., et al. Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3. Am J Hum Genet. 2005;77(1):16–26.CrossRef Google Scholar PubMed

Kono, S, Miyajima, H, Yoshida, K, et al. Mutations in a thiamine-transporter gene and Wernicke’s-like encephalopathy. N Engl J Med. 2009;360(17):1792–4.Google Scholar

Debs, R, Depienne, C, Rastetter, A, et al. Biotin-responsive basal ganglia disease in ethnic Europeans with novel SLC19A3 mutations. Arch Neurol. 2010;67(1):126–30.Google Scholar

Serrano, M, Rebollo, M, Depienne, C, et al. Reversible generalized dystonia and encephalopathy from thiamine transporter 2 deficiency. Mov Disord. 2012;27(10):1295–8.Google Scholar

Ortigoza-Escobar, JD, Serrano, M, Molero, M, et al. Thiamine transporter-2 deficiency: Outcome and treatment monitoring. Orphanet J Rare Dis. 2014;9:92.Google Scholar

Alfadhel, M, Almuntashri, M, Jadah, RH, et al. Biotin-responsive basal ganglia disease should be renamed biotin–thiamine-responsive basal ganglia disease: A retrospective review of the clinical, radiological and molecular findings of 18 new cases. Orphanet J Rare Dis. 2013;8:83.Google Scholar

Tabarki, B, Al-Shafi, S, Al-Shahwan, S, et al. Biotin-responsive basal ganglia disease revisited: Clinical, radiologic, and genetic findings. Neurology. 2013;80(3):261–7.Google Scholar

Hentati, A, Deng, HX, Hung, WY, et al. Human alpha-tocopherol transfer protein: Gene structure and mutations in familial vitamin E deficiency. Ann Neurol. 1996;39(3):295–300.Google Scholar

Harding, AE, Matthews, S, Jones, S, et al. Spinocerebellar degeneration associated with a selective defect of vitamin E absorption. N Engl J Med. 1985;313(1):32–5.Google Scholar

El Euch-Fayache, G, Bouhlal, Y, Amouri, R, Feki, M, Hentati, F. Molecular, clinical and peripheral neuropathy study of Tunisian patients with ataxia with vitamin E deficiency. Brain. 2014;137(Pt 2):402–10.Google Scholar

Becker, AE, Vargas, W, Pearson, TS. Ataxia with vitamin e deficiency may present with cervical dystonia. Tremor Other Hyperkinet Mov (NY). 2016;6:374.Google Scholar

Angelini, L, Erba, A, Mariotti, C, et al. Myoclonic dystonia as unique presentation of isolated vitamin E deficiency in a young patient. Mov Disord. 2002;17(3):612–4.Google Scholar

Mariotti, C, Gellera, C, Rimoldi, M, Mineri, R, Uziel, G, Zorzi, G, et al. Ataxia with isolated vitamin E deficiency: Neurological phenotype, clinical follow-up and novel mutations in TTPA gene in Italian families. Neurol Sci. 2004;25(3):130–7.Google Scholar

Yokota, T, Uchihara, T, Kumagai, J, et al. Postmortem study of ataxia with retinitis pigmentosa by mutation of the alpha-tocopherol transfer protein gene. J Neurol Neurosurg Psychiatry. 2000;68(4):521–5.Google Scholar

Schuelke, M. Ataxia with vitamin E deficiency. GeneReviews®. 2005;May 20 (updated 16 Oct 2013).Google Scholar

Gabsi, S, Gouider-Khouja, N, Belal, S, et al. Effect of vitamin E supplementation in patients with ataxia with vitamin E deficiency. Eur J Neurol. 2001;8(5):477–81.Google Scholar

De Vivo, DC, Trifiletti, RR, Jacobson, RI, et al. Defective glucose transport across the blood–brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med. 1991;325(10):703–9.Google Scholar

Pearson, TS, Akman, C, Hinton, VJ, Engelstad, K, De Vivo, DC. Phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS). Curr Neurol Neurosci Rep. 2013;13(4):342.Google Scholar

Suls, A, Dedeken, P, Goffin, K, et al. Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter Glut1. Brain. 2008;131(Pt 7):1831–44.Google Scholar

Pong, AW, Geary, BR, Engelstad, KM, et al. Glucose transporter type I deficiency syndrome: Epilepsy phenotypes and outcomes. Epilepsia. 2012;53(9):1503–10.Google Scholar

Pons, R, Collins, A, Rotstein, M, Engelstad, K, De Vivo, DC. The spectrum of movement disorders in Glut-1 deficiency. Mov Disord. 2010;25(3):275–81.CrossRef Google Scholar PubMed

Pearson, TS, Pons, R, Engelstad, K, et al. Paroxysmal eye–head movements in Glut1 deficiency syndrome. Neurology. 2017;88(17):1666–73.Google Scholar

Leen, WG, Klepper, J, Verbeek, MM, et al. Glucose transporter-1 deficiency syndrome: The expanding clinical and genetic spectrum of a treatable disorder. Brain. 2010;133(Pt 3):655–70.Google Scholar

Weber, YG, Storch, A, Wuttke, TV, et al. Glut1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. J Clin Invest. 2008;118(6):2157–68.Google Scholar

Perez-Duenas, B, Prior, C, Ma, Q, et al. Childhood chorea with cerebral hypotrophy: A treatable Glut1 energy failure syndrome. Arch Neurol. 2009;66(11):1410–4.Google Scholar

Friedman, JR, Thiele, EA, Wang, D, et al. Atypical Glut1 deficiency with prominent movement disorder responsive to ketogenic diet. Mov Disord. 2006;21(2):241–5.Google Scholar

Rotstein, M, Doran, J, Yang, H, et al. Glut1 deficiency and alternating hemiplegia of childhood. Neurology. 2009;73(23):2042-4.CrossRef Google Scholar PubMed

Weller, CM, Leen, WG, Neville, BG, et al. A novel SLC2A1 mutation linking hemiplegic migraine with alternating hemiplegia of childhood. Cephalalgia. 2015;35(1):10–5.Google Scholar

Urbizu, A, Cuenca-Leon, E, Raspall-Chaure, M, et al. Paroxysmal exercise-induced dyskinesia, writer’s cramp, migraine with aura and absence epilepsy in twin brothers with a novel SLC2A1 missense mutation. J Neurol Sci. 2010;295(1-2):110–3.Google Scholar

Pascual, JM, Van Heertum, RL, Wang, D, Engelstad, K, De Vivo, DC. Imaging the metabolic footprint of Glut1 deficiency on the brain. Ann Neurol. 2002;52(4):458–64.CrossRef Google Scholar PubMed

Leen, WG, Mewasingh, L, Verbeek, MM, et al. Movement disorders in Glut1 deficiency syndrome respond to the modified Atkins diet. Mov Disord. 2013;28(10):1439–42.Google Scholar

Machado, A, Chien, HF, Deguti, MM, et al. Neurological manifestations in Wilson’s disease: Report of 119 cases. Mov Disord. 2006;21(12):2192–6.Google Scholar

Taly, AB, Meenakshi-Sundaram, S, Sinha, S, Swamy, HS, Arunodaya, GR. Wilson disease: Description of 282 patients evaluated over 3 decades. Medicine. 2007;86(2):112–21.Google Scholar

Svetel, M, Kozic, D, Stefanova, E, et al. Dystonia in Wilson’s disease. Mov Disord 2001;16(4):719–23.Google Scholar

Walshe, JM, Yealland, M. Wilson’s disease: The problem of delayed diagnosis. J Neurol Neurosurg Psychiatry. 1992;55(8):692–6.Google Scholar

Pearl, PL. Monoamine neurotransmitter deficiencies. Handbook Clin Neurol. 2013;113:1819–25.Google Scholar

Ng, J, Papandreou, A, Heales, SJ, Kurian, MA. Monoamine neurotransmitter disorders: Clinical advances and future perspectives. Nature Rev Neurol. 2015;11(10):567–84.Google Scholar

Jan, MM. Misdiagnoses in children with Dopa-responsive dystonia. Pediatr Neurol. 2004;31(4):298–303.Google Scholar

Segawa, M, Nomura, Y, Nishiyama, N. Autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease). Ann Neurol. 2003;54(Suppl 6):S32–45.Google Scholar

Assmann, B, Surtees, R, Hoffmann, GF. Approach to the diagnosis of neurotransmitter diseases exemplified by the differential diagnosis of childhood-onset dystonia. Ann Neurol. 2003;54(Suppl 6):S18–24.Google Scholar

Tadic, V, Kasten, M, Bruggemann, N, et al. Dopa-responsive dystonia revisited: Diagnostic delay, residual signs, and nonmotor signs. Arch Neurol. 2012;69(12):1558–62.Google Scholar

Nygaard, TG, Marsden, CD, Fahn, S. Dopa-responsive dystonia: Long-term treatment response and prognosis. Neurology. 1991;41(2 Pt 1)):174–81.Google Scholar

Trender-Gerhard, I, Sweeney, MG, Schwingenschuh, P, et al. Autosomal-dominant GTPCH1-deficient DRD: Clinical characteristics and long-term outcome of 34 patients. J Neurol Neurosurg Psychiatry. 2009;80(8):839–45.Google Scholar

Patterson, MC, Vecchio, D, Prady, H, Abel, L, Wraith, JE. Miglustat for treatment of Niemann–Pick C disease: A randomised controlled study. Lancet Neurol. 2007;6(9):765–72.CrossRef Google Scholar PubMed

Geberhiwot, T, Moro, A, Dardis, A, et al. Consensus clinical management guidelines for Niemann–Pick disease type C. Orphanet J Rare Dis. 2018;13:50.Google Scholar

Tuschl, K, Clayton, PT, Gospe, SM Jr., Mills, PB. Dystonia/parkinsonism, hypermanganesemia, polycythemia, and chronic liver disease. GeneReviews. 2003 Jul 16 (updated Apr 14, 2016).Google Scholar

Federico, A, Dotti, MT, Gallus, GN. Cerebrotendinous xanthomatosis. GeneReviews®. 2003;Jul 16 (updated Apr 14, 2016).Google Scholar

Tabarki, B, Al-Hashem, A, Alfadhel, M. Biotin-thiamine-responsive basal ganglia disease. GeneReviews®. 2013;Nov 21 (initial posting).Google Scholar

Weiss, KH. Wilson disease GeneReviews®. 1999; October 22 (updated Jul 29, 2016).Google Scholar

Furukawa, Y. GTP Cyclohydrolase 1-deficient dopa-responsive dystonia. GeneReviews®. 2002; Feb 21 (updated Jan 24, 2019).Google Scholar

Rosenberg, E. Legacies of Garrod’s brilliance. One hundred years – and counting.J Inherit Metab Dis. 2008;31(5):574–9.Google Scholar

Garcia-Cazorla, A, Wolf, NI, Serrano, M, et al. Inborn errors of metabolism and motor disturbances in children. J Inherit Metab Dis. 2009;32(5):618–29.Google Scholar

Sedel, F, Baumann, N, Turpin, JC, et al. Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults. J Inherit Metab Dis. 2007;30(5):631–41.Google Scholar

Sedel, F, Fontaine, B, Saudubray, JM, Lyon-Caen, O. Hereditary spastic paraparesis in adults associated with inborn errors of metabolism: A diagnostic approach. J Inherit Metab Dis. 2007;30(6):855–64.Google Scholar

Sedel, F, Gourfinkel-An, I, Lyon-Caen, O, et al. Epilepsy and inborn errors of metabolism in adults: A diagnostic approach. J Inherit Metab Dis. 2007;30(6):846–54.Google Scholar

Ferreira, CR, van Karnebeek, CDM, Vockley, J, Blau, N. A proposed nosology of inborn errors of metabolism. Genet Med. 2019;21(1):102–6.Google Scholar

Mink, JW, Sanger, TD. Movement disorders: An overview. In Swaiman, K, Ashwal, S, Ferriero, D, et al., editors. Swaiman’s Pediatric Neurology, 6th edn. Elsevier; 2017, pp. 706–17.Google Scholar

Christensen, CK, Walsh, L. Movement disorders and neurometabolic diseases. Semin Pediatr Neurol. 2018;25:82–91.Google Scholar

Fernandez-Alvarez, E, Aicardi, J. Movement Disorders in Children. Mac Keith Press; 2001.Google Scholar

Yanagisawa, N. Functions and dysfunctions of the basal ganglia in humans. Proc Jpn Acad Ser B Phys Biol Sci. 2018;94(7):275–304.Google Scholar

Balint, B, Mencacci, NE, Valente, EM, et al. Dystonia. Nat Rev Dis Primers. 2018;4(1):25.Google Scholar

Lamari, F, Mochel, F, Saudubray, JM. An overview of inborn errors of complex lipid biosynthesis and remodelling. J Inherit Metab Dis. 2015;38(1):3–18.Google Scholar

Brimblecombe, KR, Cragg, SJ. The striosome and matrix compartments of the striatum: A path through the labyrinth from neurochemistry toward function. ACS Chem Neurosci. 2017;8(2):235–42.Google Scholar

Bolam, JP, Izzo, PN, Graybiel, AM. Cellular substrate of the histochemically defined striosome/matrix system of the caudate nucleus: A combined Golgi and immunocytochemical study in cat and ferret. Neuroscience. 1988;24(3):853–75.Google Scholar

Davis, MI, Puhl, HL, 3rd. Nr4a1-eGFP is a marker of striosome–matrix architecture, development and activity in the extended striatum. PLoS One. 2011;6(1):e16619.Google Scholar

Holt, DJ, Graybiel, AM, Saper, CB. Neurochemical architecture of the human striatum. J Comp Neurol. 1997;384(1):1–25.Google Scholar

Crittenden, J, Graybiel, AM. Disease-associated changes in the striosome and matrix compartments of the dorsal striatum. In Steine, H, Tseng, K, editors. Handbook of Basal Ganglia Structure and Function, 2nd edn. Amsterdam: Elsevier; 2016, pp. 801–15.Google Scholar

Holmes, MJ, Robertson, FC, Little, F, et al. Longitudinal increases of brain metabolite levels in 5–10 year old children. PLoS One. 2017;12(7):e0180973.Google Scholar

Moffett, JR, Ross, B, Arun, P, Madhavarao, CN, Namboodiri, AM. N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology. Prog Neurobiol. 2007;81(2):89–131.Google Scholar

Benarroch, EE. Basic Neurosciences with Clinical Applications. Philadelphia, PA: Butterworth-Heinemann; 2006.Google Scholar

Saudubray, JM, Garcia-Cazorla, A. Inborn errors of metabolism overview: Pathophysiology, manifestations, evaluation, and management. Pediatr Clin North Am. 2018;65(2):179–208.Google Scholar

Boycott, KM, Beaulieu, CL, Kernohan, KD, et al. Autosomal-recessive intellectual disability with cerebellar atrophy syndrome caused by mutation of the manganese and zinc transporter gene SLC39A8. Am J Hum Genet. 2015;97(6):886–93.Google Scholar

Park, JH, Hogrebe, M, Gruneberg, M, et al. SLC39A8 Deficiency: A disorder of manganese transport and glycosylation. Am J Hum Genet. 2015;97(6):894–903.CrossRef Google Scholar PubMed

Harayama, T, Riezman, H. Understanding the diversity of membrane lipid composition. Nat Rev Mol Cell Biol. 2018;19(5):281–96.Google Scholar

Sasarman, F, Maftei, C, Campeau, PM, et al. Biosynthesis of glycosaminoglycans: Associated disorders and biochemical tests. J Inherit Metab Dis. 2016;39(2):173–88.Google Scholar

Garcia-Cazorla, A, Mochel, F, Lamari, F, Saudubray, JM. The clinical spectrum of inherited diseases involved in the synthesis and remodeling of complex lipids. A tentative overview.J Inherit Metab Dis. 2015;38(1):19–40.Google Scholar

Sprecher, E, Ishida-Yamamoto, A, Mizrahi-Koren, M, et al. A mutation in SNAP29, coding for a SNARE protein involved in intracellular trafficking, causes a novel neurocutaneous syndrome characterized by cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma. Am J Hum Genet. 2005;77(2):242–51.Google Scholar

Hirst, J, Edgar, JR, Esteves, T, Darios, F, Madeo, M, Chang, J, et al. Loss of AP-5 results in accumulation of aberrant endolysosomes: Defining a new type of lysosomal storage disease. Hum Mol Genet. 2015;24(17):4984–96.Google Scholar

Stockler, S, Corvera, S, Lambright, D, Fogarty, K, Nosova, E, Leonard, D, et al. Single point mutation in Rabenosyn-5 in a female with intractable seizures and evidence of defective endocytotic trafficking. Orphanet J Rare Dis. 2014;9:141.Google Scholar

Cortes-Saladelafont, E, Lipstein, N, Garcia-Cazorla, A. Presynaptic disorders: A clinical and pathophysiological approach focused on the synaptic vesicle. J Inherit Metab Dis. 2018;41(6):1131–45.Google Scholar

Ebrahimi-Fakhari, D, Saffari, A, Wahlster, L, Lu, J, Byrne, S, Hoffmann, GF, et al. Congenital disorders of autophagy: An emerging novel class of inborn errors of neuro-metabolism. Brain. 2016;139(Pt 2):317–37.Google Scholar

Garcia-Cazorla, A, Saudubray, JM. Cellular neurometabolism: A tentative to connect cell biology and metabolism in neurology. J Inherit Metab Dis. 2018;41(6):1043–54.Google Scholar

Mochel, F, Sedel, F. Inborn errors of metabolism in adults: A diagnostic approach to neurological and psychiatric presentations. In Saudubray, JM, Baumgartner, M, Walter, JH, editors. Inborn Metabolic Diseases: Diagnosis and Treatment. Berlin: Springer-Verlag; 2016, pp. 71–89.Google Scholar

Albanese, A, Bhatia, K, Bressman, SB, et al. Phenomenology and classification of dystonia: A consensus update. Mov Disord. 2013;28(7):863–73.Google Scholar

Jinnah, HA, Albanese, A. The new classification system for the dystonias: Why was it needed and how was it developed? Mov Disord Clin Pract. 2014;1(4):280–4.Google Scholar

Garcia-Cazorla, A, Duarte, ST. Parkinsonism and inborn errors of metabolism. J Inherit Metab Dis. 2014;37(4):627–42.Google Scholar

Poretti, A, Boltshauser, E, Huisman, TA. Prenatal cerebellar disruptions: Neuroimaging spectrum of findings in correlation with likely mechanisms and etiologies of injury. Neuroimaging Clin N Am. 2016;26(3):359–72.Google Scholar

Synofzik, M, Nemeth, AH. Recessive ataxias. Handb Clin Neurol. 2018;155:73–89.Google Scholar

Jen, JC, Wan, J. Episodic ataxias. Handb Clin Neurol. 2018;155:205–15.Google Scholar

Ghaoui, R, Sue, CM. Movement disorders in mitochondrial disease. J Neurol. 2018;265(5):1230–40.Google Scholar

Sanderson, S, Green, A, Preece, MA, Burton, H. The incidence of inherited metabolic disorders in the West Midlands, UK. Arch Dis Child. 2006;91(11):896–9.Google Scholar

Gouider-Khouja, N, Kraoua, I, Benrhouma, H, Fraj, N, Rouissi, A. Movement disorders in neuro-metabolic diseases. Eur J Paediatr Neurol. 2010;14(4):304–7.Google Scholar

Jinnah, HA, Albanese, A, Bhatia, KP, et al. Treatable inherited rare movement disorders. Mov Disord. 2018;33(1):21–35.Google Scholar

Marras, C, Lang, A, van de Warrenburg, BP, et al. Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force. Mov Disord. 2016;31(4):436–57.CrossRef Google Scholar PubMed

El Euch-Fayache, G, Bouhlal, Y, Amouri, R, Feki, M, Hentati, F. Molecular, clinical and peripheral neuropathy study of Tunisian patients with ataxia with vitamin E deficiency. Brain. 2014;137(Pt 2):402–10.Google Scholar

Lee, J, Hegele, RA. Abetalipoproteinemia and homozygous hypobetalipoproteinemia: A framework for diagnosis and management. J Inherit Metab Dis. 2014;37(3):333–9.Google Scholar

Albanese, A, Bhatia, K, Bressman, SB, et al. Phenomenology and classification of dystonia: A consensus update. Mov Disord. 2013;28(7):863–73.Google Scholar

Wijemanne, S, Jankovic, J. Dopa-responsive dystonia: Clinical and genetic heterogeneity. Nat Rev Neurol. 2015;11(7):414–24.Google Scholar

Gitiaux, C, Roze, E, Kinugawa, K, et al. Spectrum of movement disorders associated with glutaric aciduria type 1: A study of 16 patients. Mov Disord. 2008;23(16):2392–7.Google Scholar

Kolker, S, Valayannopoulos, V, Burlina, AB, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: The evolving clinical phenotype. J Inherit Metab Dis. 2015;38(6):1059–74.Google Scholar

Martikainen, MH, Ng, YS, Gorman, GS, et al. Clinical, genetic, and radiological features of extrapyramidal movement disorders in mitochondrial disease. JAMA Neurol. 2016;73(6):668–74.Google Scholar

Ng, J, Heales, SJ, Kurian, MA. Clinical features and pharmacotherapy of childhood monoamine neurotransmitter disorders. Paediatr Drugs. 2014;16(4):275–91.Google Scholar

Jinnah, HA, Visser, JE, Harris, JC, et al. Delineation of the motor disorder of Lesch–Nyhan disease. Brain. 2006;129(Pt 5):1201–17.Google Scholar

Mercimek-Mahmutoglu, S, Stoeckler-Ipsiroglu, S, Adami, A, et al. GAMT deficiency: Features, treatment, and outcome in an inborn error of creatine synthesis. Neurology. 2006;67(3):480–4.Google Scholar

Allen, NM, Lin, JP, Lynch, T, King, MD. Status dystonicus: A practice guide. Dev Med Child Neurol. 2014;56(2):105–12.Google Scholar

Sanger, TD, Chen, D, Fehlings, DL, et al. Definition and classification of hyperkinetic movements in childhood. Mov Disord. 2010;25(11):1538–49.Google Scholar

Crossman, AR. Functional anatomy of movement disorders. J Anat. 2000;196 (Pt 4):519–25.Google Scholar

Munchau, A. Transient (benign) infantile chorea – a physiological phenomenon during motor development? International Symposium on Pediatric Movement Disorders. Barcelona: The Movement Disorder Society; 2004.Google Scholar

Klepper, J, Leiendecker, B, Eltze, C, Heussinger, N. Paroxysmal nonepileptic events in Glut1 deficiency. Mov Disord Clin Pract. 2016;3(6):607–10.Google Scholar

Keogh, MJ, Morris, CM, Chinnery, PF. Neuroferritinopathy. Int Rev Neurobiol. 2013;110:91–123.Google Scholar

Postuma, RB, Berg, D, Stern, M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–601.Google Scholar

Di Meo, I, Tiranti, V. Classification and molecular pathogenesis of NBIA syndromes. Eur J Paediatr Neurol. 2018;22(2):272–84.Google Scholar

Ebrahimi-Fakhari, D, Hildebrandt, C, Davis, PE, et al. The spectrum of movement disorders in childhood-onset lysosomal storage diseases. Mov Disord Clin Pract. 2018;5(2):149–55.Google Scholar

Garcia-Cazorla, A, Duarte, ST. Parkinsonism and inborn errors of metabolism. J Inherit Metab Dis. 2014;37(4):627–42.Google Scholar

Ghaoui, R, Sue, CM. Movement disorders in mitochondrial disease. J Neurol. 2018;265(5):1230–40.Google Scholar

Sidransky, E, Nalls, MA, Aasly, JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med. 2009;361(17):1651–61.Google Scholar

Bhatia, KP, Bain, P, Bajaj, N, et al. Consensus statement on the classification of tremors from the Task Force on Tremor of the International Parkinson and Movement Disorder Society. Mov Disord. 2018;33(1):75–87.Google Scholar

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Wilson’s disease. J Hepatol. 2012;56(3):671–85.Google Scholar

Tilikete, C, Desestret, V. Hypertrophic olivary degeneration and palatal or oculopalatal tremor. Front Neurol. 2017;8:302.Google Scholar

Mink, JW, Augustine, EF, Adams, HR, Marshall, FJ, Kwon, JM. Classification and natural history of the neuronal ceroid lipofuscinoses. J Child Neurol. 2013;28(9):1101–5.Google Scholar

Ferreira, CR, Gahl, WA. Lysosomal storage diseases. Transl Sci Rare Dis. 2017;2(1–2):1–71.Google Scholar

Leach, EL, Shevell, M, Bowden, K, Stockler-Ipsiroglu, S, van Karnebeek, CD. Treatable inborn errors of metabolism presenting as cerebral palsy mimics: Systematic literature review. Orphanet J Rare Dis. 2014;9:197.Google Scholar

Rosenbaum, P, Paneth, N, Leviton, A, et al. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl. 2007;109:8–14.Google Scholar

Kolker, S, Christensen, E, Leonard, JV, et al. Diagnosis and management of glutaric aciduria type I: Revised recommendations. J Inherit Metab Dis. 2011;34(3):677–94.Google Scholar

Alfadhel, M, Almuntashri, M, Jadah, RH, et al. Biotin-responsive basal ganglia disease should be renamed biotin–thiamine-responsive basal ganglia disease: A retrospective review of the clinical, radiological and molecular findings of 18 new cases. Orphanet J Rare Dis. 2013;8:83.Google Scholar

Pons, R, Collins, A, Rotstein, M, Engelstad, K, De Vivo, DC. The spectrum of movement disorders in Glut-1 deficiency. Mov Disord. 2010;25(3):275–81.Google Scholar

Castiglioni, C, Verrigni, D, Okuma, C, et al. Pyruvate dehydrogenase deficiency presenting as isolated paroxysmal exercise induced dystonia successfully reversed with thiamine supplementation. Case report and mini-review. Eur J Paediatr Neurol. 2015;19(5):497–503.Google Scholar

Darras, BT, Ampola, MG, Dietz, WH, Gilmore, HE. Intermittent dystonia in Hartnup disease. Pediatr Neurol. 1989;5(2):118–20.Google Scholar

Carecchio, M, Schneider, SA, Chan, H, et al. Movement disorders in adult surviving patients with maple syrup urine disease. Mov Disord. 2011;26(7):1324–8.Google Scholar

Slow, EJ, Lang, AE. Oculogyric crises: A review of phenomenology, etiology, pathogenesis, and treatment. Mov Disord. 2017;32(2):193–202.Google Scholar

Watson, MS, Mann, MY, Lloyd-Puryear, MA, Rinaldo, P, Howell, RR.Executive summary. Genet Med. 2006;8:1S.Google Scholar

Therrell, BL, Padilla, CD, Loeber, JG, et al. Current status of newborn screening worldwide: 2015. Semin Perinatol. 2015;39(3):171–87.CrossRef Google Scholar PubMed

Neveling, K, Feenstra, I, Gilissen, C, et al. A post-hoc comparison of the utility of Sanger sequencing and exome sequencing for the diagnosis of heterogeneous diseases. Hum Mutat. 2013;34(12):1721–6.Google Scholar

van Egmond, ME, Lugtenberg, CHA, Brouwer, OF, et al. A post hoc study on gene panel analysis for the diagnosis of dystonia. Mov Disord. 2017;32(4):569–75.Google Scholar

Parikh, S, Bernard, G, Leventer, RJ, et al. A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephelopathies. Mol Genet Metab. 2015;114(4):501–15.Google Scholar

Sedel, F, Saudubray, JM, Roze, E, Agid, Y, Vidailhet, M. Movement disorders and inborn errors of metabolism in adults: A diagnostic approach. J Inherit Metab Dis. 2008;31(3):308–18.Google Scholar

van der Knaap, MS, Breiter, SN, Naidu, S, Hart, AA, Valk, J. Defining and categorizing leukoencephalopathies of unknown origin: MR imaging approach. Radiology. 1999;213(1):121–33.Google Scholar

van der Knaap, MS, Valk, J. Magnetic Resonance of Myelination and Myelin Disorders. 3rd edn. Berlin: Springer; 2005.Google Scholar

Barkovich, AJ, Metabolic, Patay Z., Toxic, and autoimmune/inflammatory brain disorders. In Barkovich, AJ, Raybaud, C, editors. Pediatric Neuroimaging. Philadelphia, PA: Wolters Kluwer; 2019, pp. 405–632.Google Scholar

Yang, E, Prabhu, SP. Imaging manifestations of the leukodystrophies, inherited disorders of white matter. Radiol Clin North Am. 2014;52(2):279–319.Google Scholar

Barkovich, MJ, Barkovich, AJ. Normal development of the fetal, neonatal, and infant brain, skull, and spine. In Barkovich, AJ, Raybaud, C, editors. Pediatric Neuroimaging. Philadelphia: Wolters Kluwer; 2019, pp. 18–80.Google Scholar

Haacke, EM, Mittal, S, Wu, Z, Neelavalli, J, Cheng, YC. Susceptibility-weighted imaging: Technical aspects and clinical applications, part 1. AJNR Am J Neuroradiol. 2009;30(1):19–30.Google Scholar

Mittal, S, Wu, Z, Neelavalli, J, Haacke, EM. Susceptibility-weighted imaging: Technical aspects and clinical applications, part 2. AJNR Am J Neuroradiol. 2009;30(2):232–52.Google Scholar

Aoki, S, Okada, Y, Nishimura, K, et al. Normal deposition of brain iron in childhood and adolescence: MR imaging at 1.5 T. Radiology. 1989;172(2):381–5.Google Scholar

Aquino, D, Bizzi, A, Grisoli, M, et al. Age-related iron deposition in the basal ganglia: Quantitative analysis in healthy subjects. Radiology. 2009;252(1):165–72.Google Scholar

Harder, SL, Hopp, KM, Ward, H, et al. Mineralization of the deep gray matter with age: A retrospective review with susceptibility-weighted MR imaging. AJNR Am J Neuroradiol. 2008;29(1):176–83.Google Scholar

Legido, A, Zimmerman, RA, Packer, RJ, et al. Significance of basal ganglia calcification on computed tomography in children. Pediatr Neurosci. 1988;14(2):64–70.Google Scholar

McKinney, AM. Basal ganglia: Physiologic calcification. In McKinney, AM, editor. Atlas of Normal Imaging Variation of the Brain, Skull, and Craniocervical Vasculature. Berlin: Springer; 2017, pp. 427–40.Google Scholar

Chen, W, Zhu, W, Kovanlikaya, I, et al. Intracranial calcifications and hemorrhages: Characterization with quantitative susceptibility mapping. Radiology. 2014;270(2):496–505.Google Scholar

Saudubray, JM, van den Bergh, G, Walter, JH. Inborn Metabolic Diseases: Diagnosis and Treatment, 5th edn. Berlin: Springer; 2012.Google Scholar

Brismar, J, Ozand, PT. CT and MR of the brain in the diagnosis of organic acidemias. Experiences from 107 patients. Brain Dev. 1994;16 Suppl:104–24.Google Scholar

Harting, I, Neumaier-Probst, E, Seitz, A, et al. Dynamic changes of striatal and extrastriatal abnormalities in glutaric aciduria type I. Brain. 2009;132(Pt 7):1764–82.Google Scholar

Harting, I, Seitz, A, Geb, S, et al. Looking beyond the basal ganglia: The spectrum of MRI changes in methylmalonic acidaemia. J Inherit Metab Dis. 2008;31(3):368–78.Google Scholar

Radmanesh, A, Zaman, T, Ghanaati, H, et al. Methylmalonic acidemia: Brain imaging findings in 52 children and a review of the literature. Pediatr Radiol. 2008;38(10):1054–61.Google Scholar

Schreiber, J, Chapman, KA, Summar, ML, et al. Neurologic considerations in propionic acidemia. Mol Genet Metab. 2012;105(1):10–5.Google Scholar

Strauss, KA, Lazovic, J, Wintermark, M, Morton, DH. Multimodal imaging of striatal degeneration in Amish patients with glutaryl-CoA dehydrogenase deficiency. Brain. 2007;130(Pt 7):1905–20.Google Scholar

Bonfante, E, Koenig, MK, Adejumo, RB, Perinjelil, V, Riascos, RF. The neuroimaging of Leigh syndrome: Case series and review of the literature. Pediatr Radiol. 2016;46(4):443–51.Google Scholar

Bricout, M, Grevent, D, Lebre, AS, et al. Brain imaging in mitochondrial respiratory chain deficiency: Combination of brain MRI features as a useful tool for genotype/phenotype correlations. J Med Genet. 2014;51(7):429–35.Google Scholar

Morava, E, van den Heuvel, L, Hol, F, et al. Mitochondrial disease criteria: Diagnostic applications in children. Neurology. 2006;67(10):1823–6.Google Scholar

Tabarki, B, Al-Shafi, S, Al-Shahwan, S, et al. Biotin-responsive basal ganglia disease revisited: Clinical, radiologic, and genetic findings. Neurology. 2013;80(3):261–7.Google Scholar

Kobayashi, O, Takashima, S. Thalamic hyperdensity on CT in infantile GM1-gangliosidosis. Brain Dev. 1994;16(6):472–4.Google Scholar

Muthane, U, Chickabasaviah, Y, Kaneski, C, et al. Clinical features of adult GM1 gangliosidosis: Report of three Indian patients and review of 40 cases. Mov Disord. 2004;19(11):1334–41.Google Scholar

van Wassenaer-van Hall, HN, van den Heuvel, AG, Algra, A, Hoogenraad, TU, Mali, WP. Wilson disease: Findings at MR imaging and CT of the brain with clinical correlation. Radiology. 1996;198(2):531–6.Google Scholar

Prashanth, LK, Sinha, S, Taly, AB, Vasudev, MK. Do MRI features distinguish Wilson’s disease from other early onset extrapyramidal disorders? An analysis of 100 cases. Mov Disord. 2010;25(6):672–8.Google Scholar

Skowronska, M, Litwin, T, Dziezyc, K, Wierzchowska, A, Czlonkowska, A. Does brain degeneration in Wilson disease involve not only copper but also iron accumulation? Neurol Neurochir Pol. 2013;47(6):542–6.Google Scholar

Mercimek-Mahmutoglu, S, Stoeckler-Ipsiroglu, S, Adami, A, et al. GAMT deficiency: Features, treatment, and outcome in an inborn error of creatine synthesis. Neurology. 2006;67(3):480–4.Google Scholar

van Toorn, R, Brink, P, Smith, J, Ackermann, C, Solomons, R. Bilirubin-induced neurological dysfunction: A clinico-radiological-neurophysiological correlation in 30 consecutive children. J Child Neurol. 2016;31(14):1579–83.Google Scholar

Zuccoli, G, Santa Cruz, D, Bertolini, M, et al. MR imaging findings in 56 patients with Wernicke encephalopathy: Nonalcoholics may differ from alcoholics. AJNR Am J Neuroradiol. 2009;30(1):171–6.Google Scholar

Lai, PH, Tien, RD, Chang, MH, et al. Chorea-ballismus with nonketotic hyperglycemia in primary diabetes mellitus. AJNR Am J Neuroradiol. 1996;17(6):1057–64.Google Scholar

Pearl, PL, Vezina, LG, Saneto, RP, et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia. 2009;50(2):184–94.Google Scholar

Krageloh-Mann, I, Horber, V. The role of magnetic resonance imaging in elucidating the pathogenesis of cerebral palsy: A systematic review. Dev Med Child Neurol. 2007;49(2):144–51.Google Scholar

Schwartz, ES, Barkovich, AJ. Brain and spine injuries in infancy and childhood. In Barkovich, AJ, Raybaud, C, editors. Pediatric Neuroimaging. Philadelphia, PA: Wolters Kluwer; 2019, pp. 405–632.Google Scholar

Gonzalez-Alegre, P, Afifi, AK. Clinical characteristics of childhood-onset (juvenile) Huntington disease: Report of 12 patients and review of the literature. J Child Neurol. 2006;21(3):223–9.Google Scholar

Basel-Vanagaite, L, Muncher, L, Straussberg, R, et al. Mutated NUP62 causes autosomal recessive infantile bilateral striatal necrosis. Ann Neurol. 2006;60(2):214–22.Google Scholar

Neilson, DE. The interplay of infection and genetics in acute necrotizing encephalopathy. Curr Opin Pediatr. 2010;22(6):751–7.Google Scholar

Gregory, A, Hayflick, S. Neurodegeneration with brain iron accumulation. GeneReviews®. 2013;Feb 28 (updated Oct 21, 2019).Google Scholar

Di Meo, I, Tiranti, V. Classification and molecular pathogenesis of NBIA syndromes. Eur J Paediatr Neurol. 2018;22(2):272–84.Google Scholar

Kruer, MC, Boddaert, N, Schneider, SA, et al. Neuroimaging features of neurodegeneration with brain iron accumulation. AJNR Am J Neuroradiol. 2012;33(3):407–14.Google Scholar

Hayflick, SJ, Hartman, M, Coryell, J, Gitschier, J, Brain, Rowley H. MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. AJNR Am J Neuroradiol. 2006;27(6):1230–3.Google Scholar

Hayflick, SJ, Westaway, SK, Levinson, B, et al. Genetic, clinical, and radiographic delineation of Hallervorden–Spatz syndrome. N Engl J Med. 2003;348(1):33–40.Google Scholar

Iodice, A, Spagnoli, C, Salerno, GG, et al. Infantile neuroaxonal dystrophy and PLA2G6-associated neurodegeneration: An update for the diagnosis. Brain Dev. 2017;39(2):93–100.Google Scholar

McNeill, A, Birchall, D, Hayflick, SJ, et al. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology. 2008;70(18):1614–9.Google Scholar

Wynn, DP, Pulst, SM. A novel WDR45 mutation in a patient with beta-propeller protein-associated neurodegeneration. Neurol Genet. 2017;3(1):e124.Google Scholar

Quadri, M, Federico, A, Zhao, T, et al. Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. Am J Hum Genet. 2012;90(3):467–77.Google Scholar

Tuschl, K, Meyer, E, Valdivia, LE, et al. Mutations in SLC39A14 disrupt manganese homeostasis and cause childhood-onset parkinsonism–dystonia. Nat Commun. 2016;7:11601.Google Scholar

Rodan, LH, Hauptman, M, D’Gama, AM, et al. Novel founder intronic variant in SLC39A14 in two families causing manganism and potential treatment strategies. Mol Genet Metab. 2018;124(2):161–7.Google Scholar

Ramos, EM, Carecchio, M, Lemos, R, et al. Primary brain calcification: An international study reporting novel variants and associated phenotypes. Eur J Hum Genet. 2018;26(10):1462–77.Google Scholar

Yao, XP, Cheng, X, Wang, C, et al. Mutations in MYORG cause autosomal recessive primary familial brain calcification. Neuron. 2018;98(6):1116–23 e5.Google Scholar

Steenweg, ME, Vanderver, A, Blaser, S, et al. Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain. 2010;133(10):2971–82.Google Scholar

De Grandis, E, Di Rocco, M, Pessagno, A, Veneselli, E, Rossi, A. MR imaging findings in 2 cases of late infantile GM1 gangliosidosis. AJNR Am J Neuroradiol. 2009;30(7):1325–7.Google Scholar

Livingston, JH, Stivaros, S, van der Knaap, MS, Crow, YJ. Recognizable phenotypes associated with intracranial calcification. Dev Med Child Neurol. 2013;55(1):46–57.Google Scholar

Nelson, MD, Jr., Wolff, JA, Cross, CA, Donnell, GN, Kaufman, FR. Galactosemia: Evaluation with MR imaging. Radiology. 1992;184(1):255–61.Google Scholar

Berry, GT, Hunter, JV, Wang, Z, et al. In vivo evidence of brain galactitol accumulation in an infant with galactosemia and encephalopathy. J Pediatr. 2001;138(2):260–2.Google Scholar

Morton, DH, Strauss, KA, Robinson, DL, Puffenberger, EG, Kelley, RI. Diagnosis and treatment of maple syrup disease: A study of 36 patients. Pediatrics. 2002;109(6):999–1008.Google Scholar

Carecchio, M, Schneider, SA, Chan, H, et al. Movement disorders in adult surviving patients with maple syrup urine disease. Mov Disord. 2011;26(7):1324–8.Google Scholar

Cavalleri, F, Berardi, A, Burlina, AB, Ferrari, F, Mavilla, L. Diffusion-weighted MRI of maple syrup urine disease encephalopathy. Neuroradiology. 2002;44(6):499–502.Google Scholar

Khong, PL, Lam, BC, Chung, BH, Wong, KY, Ooi, GC. Diffusion-weighted MR imaging in neonatal nonketotic hyperglycinemia. AJNR Am J Neuroradiol. 2003;24(6):1181–3.Google Scholar

Santavuori, P, Vanhanen, SL, Autti, T. Clinical and neuroradiological diagnostic aspects of neuronal ceroid lipofuscinoses disorders. Eur J Paediatr Neurol. 2001;5 Suppl A:157–61.Google Scholar

Fu, J, Dumitrescu, AM. Inherited defects in thyroid hormone cell-membrane transport and metabolism. Best Pract Res Clin Endocrinol Metab. 2014;28(2):189–201.Google Scholar

Vaurs-Barriere, C, Deville, M, Sarret, C, et al. Pelizaeus–Merzbacher-like disease presentation of MCT8 mutated male subjects. Ann Neurol. 2009;65(1):114–8.Google Scholar

Hao, J, Kelly, DI, Su, J, Pascual, JM. Clinical aspects of glucose transporter type 1 deficiency: Information from a global registry. JAMA Neurol. 2017;74(6):727–32.Google Scholar

Group, N-CGW, Wraith, JE, Baumgartner, MR, et al. Recommendations on the diagnosis and management of Niemann–Pick disease type C. Mol Genet Metab. 2009;98(1–2):152–65.Google Scholar

Harris, JC, Lee, RR, Jinnah, HA, et al. Craniocerebral magnetic resonance imaging measurement and findings in Lesch–Nyhan syndrome. Arch Neurol. 1998;55(4):547–53.Google Scholar

Jurecka, A, Zikanova, M, Kmoch, S, Tylki-Szymanska, A. Adenylosuccinate lyase deficiency. J Inherit Metab Dis. 2015;38(2):231–42.Google Scholar

Waisbren, SE, Prabhu, SP, Greenstein, P, et al. Improved measurement of brain phenylalanine and tyrosine related to neuropsychological functioning in phenylketonuria. JIMD Rep. 2017;34:77–86.Google Scholar

Jang, D-H. AB052. Application of facial dysmorphology analysis technology (Face2gene) in Korean rare genetic diseases. Ann Transl Med. 2017;Sep 5(Suppl 2):AB052.Google Scholar

Faria, AV, Liang, Z, Miller, MI, Mori, S. Brain MRI pattern recognition translated to clinical scenarios. Front Neurosci. 2017;11:578.Google Scholar

Garcia-Cazorla, A, Wolf, NI, Mochel, F, Hoffmann, GF. Neurological disease. In Hoffmann, GF, editor. Inherited Metabolic Diseases. Berlin: Springer-Verlag; 2017, pp. 251–92.Google Scholar

Ebrahimi-Fakhari, D, Van Karnebeek, C, Munchau, A. Movement disorders in treatable inborn errors of metabolism. Mov Disord. 2019;34:598–613.Google Scholar

Christensen, CK, Walsh, L. Movement disorders and neurometabolic diseases. Semin Pediatr Neurol. 2018;25:82–91.Google Scholar

Jinnah, HA, Albanese, A, Bhatia, KP, et al. Treatable inherited rare movement disorders. Mov Disord. 2018;33(1):21–35.Google Scholar

Lee, JJY, Wasserman, WW, Hoffmann, GF, van Karnebeek, CDM, Blau, N. Knowledge base and mini-expert platform for the diagnosis of inborn errors of metabolism. Genet Med. 2018;20(1):151–8.Google Scholar

Ferreira, CR, van Karnebeek, CDM, Vockley, J, Blau, N. A proposed nosology of inborn errors of metabolism. Genet Med. 2019;21(1):102–6.Google Scholar

Ferreira, CR, Hoffmann, GF, Blau, N. Clinical and biochemical footprints of inherited metabolic diseases. I. Movement disorders. Mol Genet Metab. 2019;127(1):28–30.Google Scholar

Hoffmann, FG, Blau, N. Signs and symptoms of neurotransmitter disorders: Approach to diagnosis. In Hoffmann, FG, Blau, N, editors. Congenital Neurotransmitter Disorders: A Clinical Approach. Huppauge, NY: Nova Publishers Inc; 2014.Google Scholar

Wevers, RA, Blau, N. Think big: Think omics. J Inherit Metab Dis. 2018;41(3):281–3.Google Scholar

Pareek, CS, Smoczynski, R, Tretyn, A. Sequencing technologies and genome sequencing. J Appl Genet. 2011;52(4):413–35.Google Scholar

van Diemen, CC, Kerstjens-Frederikse, WS, Bergman, KA, et al. Rapid targeted genomics in critically ill newborns. Pediatrics. 2017;140(4).Google Scholar

Montaut, S, Tranchant, C, Drouot, N, et al. Assessment of a targeted gene panel for identification of genes associated with movement disorders. JAMA Neurol. 2018;75(10):1234–45.CrossRef Google Scholar PubMed

Richards, S, Aziz, N, Bale, S, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24.Google Scholar

Biesecker, LG, Nussbaum, RL, Rehm, HL. Distinguishing variant pathogenicity from genetic diagnosis: How to know whether a variant causes a condition. JAMA. 2018;320(18):1929–30.CrossRef Google Scholar PubMed

Zeiger, WA, Jamal, NI, Scheuner, MT, et al. Probable diagnosis of a patient with Niemann–Pick disease type C: Managing pitfalls of exome sequencing. JIMD Rep. 2018;41:47–51.Google Scholar

Dale, RC, Grattan-Smith, P, Nicholson, M, Peters, GB. Microdeletions detected using chromosome microarray in children with suspected genetic movement disorders: A single-centre study. Dev Med Child Neurol. 2012;54(7):618–23.Google Scholar

Asmus, F, Hjermind, LE, Dupont, E, et al. Genomic deletion size at the epsilon-sarcoglycan locus determines the clinical phenotype. Brain. 2007;130(Pt 10):2736–45.Google Scholar

Campbell, IM, Yatsenko, SA, Hixson, P, et al. Novel 9q34.11 gene deletions encompassing combinations of four Mendelian disease genes: STXBP1, SPTAN1, ENG, and TOR1A. Genet Med. 2012;14(10):868–76.Google Scholar

Poisson, A, Lesca, G, Chatron, N, et al. 12q13.12q13.13 microdeletion encompassing ACVRL1 and SCN8A genes: Clinical report of a new contiguous gene syndrome. Eur J Med Genet. 2019;62(11):103565.Google Scholar

Kharbanda, M, Hermanns, P, Jones, J, Pohlenz, J, Horrocks, I, Donaldson, M. A further case of brain–lung–thyroid syndrome with deletion proximal to NKX2-1. Eur J Med Genet. 2017;60(5):257–60.Google Scholar

Kremer, LS, Bader, DM, Mertes, C, et al. Genetic diagnosis of Mendelian disorders via RNA sequencing. Nat Commun. 2017;8:15824.Google Scholar

Cummings, BB, Marshall, JL, Tukiainen, T, et al. Improving genetic diagnosis in Mendelian disease with transcriptome sequencing. Sci Transl Med. 2017;9(386): pii: eaal5209.Google Scholar

Bergant, G, Maver, A, Lovrecic, L, Comprehensive use of extended exome analysis improves diagnostic yield in rare disease: A retrospective survey in 1,059 cases. Genet Med. 2018;20(3):303–12.Google Scholar

Cordeiro, D, Bullivant, G, Siriwardena, K, et al. Genetic landscape of pediatric movement disorders and management implications. Neurol Genet. 2018;4(5):e265.CrossRef Google Scholar PubMed

Mercimek-Mahmutoglu, S, Sidky, S, Hyland, K, et al. Prevalence of inherited neurotransmitter disorders in patients with movement disorders and epilepsy: A retrospective cohort study. Orphanet J Rare Dis. 2015;10:12.Google Scholar

Reid, ES, Papandreou, A, Drury, S, et al. Advantages and pitfalls of an extended gene panel for investigating complex neurometabolic phenotypes. Brain. 2016;139(11):2844–54.Google Scholar

van Egmond, ME, Lugtenberg, CHA, Brouwer, OF, et al. A post hoc study on gene panel analysis for the diagnosis of dystonia. Mov Disord. 2017;32(4):569–75.Google Scholar

Bodzioch, M, Lapicka-Bodzioch, K, Rudzinska, M, et al. Severe dystonic encephalopathy without hyperphenylalaninemia associated with an 18-bp deletion within the proximal GCH1 promoter. Mov Disord. 2011;26(2):337–40.Google Scholar

Willemsen, MA, Verbeek, MM, Kamsteeg, EJ, et al. Tyrosine hydroxylase deficiency: A treatable disorder of brain catecholamine biosynthesis. Brain. 2010;133(Pt 6):1810–22.Google Scholar

Mukherjee, S, Dutta, S, Majumdar, S, et al. Genetic defects in Indian Wilson disease patients and genotype–phenotype correlation. Parkinsonism Relat Disord. 2014;20(1):75–81.Google Scholar

Grieco, GS, Gagliardi, S, Ricca, I, et al. New CACNA1A deletions are associated to migraine phenotypes. J Headache Pain. 2018;19(1):75.Google Scholar

Koenig, MK. Presentation and diagnosis of mitochondrial disorders in children. Pediatr Neurol. 2008;38(5):305–13.CrossRef Google Scholar PubMed

Theunissen, TEJ, Nguyen, M, Kamps, R, et al. Whole exome sequencing is the preferred strategy to identify the genetic defect in patients with a probable or possible mitochondrial cause. Front Genet. 2018;9:400.Google Scholar

Coutelier, M, Goizet, C, Durr, A, et al. Alteration of ornithine metabolism leads to dominant and recessive hereditary spastic paraplegia. Brain. 2015;138(Pt 8):2191–205.Google Scholar

Falkenberg, KD, Braverman, NE, Moser, AB, et al. Allelic expression imbalance promoting a mutant PEX6 allele causes Zellweger spectrum disorder. Am J Hum Genet. 2017;101(6):965–76.CrossRef Google Scholar PubMed

Cen, Z, Jiang, Z, Chen, Y, et al. Intronic pentanucleotide TTTCA repeat insertion in the SAMD12 gene causes familial cortical myoclonic tremor with epilepsy type 1. Brain. 2018;141(8):2280–8.Google Scholar

LaCroix, AJ, Stabley, D, Sahraoui, R, et al. GGC repeat expansion and exon 1 methylation of XYLT1 is a common pathogenic variant in Baratela–Scott syndrome. Am J Hum Genet. 2019;104(1):35–44.Google Scholar

Middleton, A, Morley, KI, Bragin, E, et al. Attitudes of nearly 7000 health professionals, genomic researchers and publics toward the return of incidental results from sequencing research. Eur J Hum Genet. 2016;24(1):21–9.CrossRef Google Scholar PubMed

Kalia, SS, Adelman, K, Bale, SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): A policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2017;19(2):249–55.CrossRef Google Scholar PubMed

Ghosh, A, Schlecht, H, Heptinstall, LE, et al. Diagnosing childhood-onset inborn errors of metabolism by next-generation sequencing. Arch Dis Child. 2017;102(11):1019–29.Google Scholar

Parikh, S, Goldstein, A, Koenig, MK, et al. Diagnosis and management of mitochondrial disease: A consensus statement from the Mitochondrial Medicine Society. Genet Med. 2015;17(9):689–701.Google Scholar

de Koning, TJ. Amino acid synthesis deficiencies. J Inherit Metab Dis. 2017;40(4):609–20.Google Scholar

Dard, R, Mignot, C, Durr, A, et al. Relapsing encephalopathy with cerebellar ataxia related to an ATP1A3 mutation. Dev Med Child Neurol. 2015;57(12):1183–6.Google Scholar

Boemer, F, Fasquelle, C, d’Otreppe, S, et al. A next-generation newborn screening pilot study: NGS on dried blood spots detects causal mutations in patients with inherited metabolic diseases. Sci Rep. 2017;7(1):17641.Google Scholar

van Karnebeek, CDM, Wortmann, SB, Tarailo-Graovac, M, et al. The role of the clinician in the multi-omics era: Are you ready? J Inherit Metab Dis. 2018;41(3):571–82.Google Scholar

Poretti, A, Benson, JE, Huisman, TA, Boltshauser, E. Acute ataxia in children: Approach to clinical presentation and role of additional investigations. Neuropediatrics. 2013;44(3):127–41.Google Scholar

Garcia-Cazorla, A, Wolf, NI, Serrano, M, et al. Inborn errors of metabolism and motor disturbances in children. J Inherit Metab Dis. 2009;32(5):618–29.Google Scholar

Saudubray, JM, Sedel, F, Walter, JH. Clinical approach to treatable inborn metabolic diseases: An introduction. J Inherit Metab Dis. 2006;29(2–3):261–74.Google Scholar

Parker, CC, Evans, OB. Metabolic disorders causing childhood ataxia. Semin Pediatr Neurol. 2003;10(3):193–9.Google Scholar

van Gaalen, J, Kerstens, FG, Maas, RP, Harmark, L, van de Warrenburg, BP. Drug-induced cerebellar ataxia: A systematic review. CNS Drugs. 2014;28(12):1139–53.Google Scholar

Gray, RG, Preece, MA, Green, SH, et al. Inborn errors of metabolism as a cause of neurological disease in adults: An approach to investigation. J Neurol Neurosurg Psychiatry. 2000;69(1):5–12.Google Scholar

Espinos, C, Pineda, M, Martinez-Rubio, D, et al. Mutations in the urocanase gene UROC1 are associated with urocanic aciduria. J Med Genet. 2009;46(6):407–11.Google Scholar

Cheon, CK, Lee, BH, Ko, JM, Kim, HJ, Yoo, HW. Novel mutation in SLC6A19 causing late-onset seizures in Hartnup disorder. Pediatr Neurol. 2010;42(5):369–71.Google Scholar

Strauss, KA, Puffenberger, EG, Morton, DH. Maple syrup urine disease. GeneReviews®. 2006;Jan 30 (updated May 9, 2013).Google Scholar

Simon, E, Flaschker, N, Schadewaldt, P, Langenbeck, U, Wendel, U. Variant maple syrup urine disease (MSUD): The entire spectrum. J Inherit Metab Dis. 2006;29(6):716–24.Google Scholar

Superti-Furga, A, Hoffmann, GF. Glutaric aciduria type 1 (glutaryl-CoA-dehydrogenase deficiency): Advances and unanswered questions. Report from an international meeting. Eur J Pediatr. 1997;156(11):821–8.Google Scholar

Rowe, PC, Newman, SL, Brusilow, SW. Natural history of symptomatic partial ornithine transcarbamylase deficiency. N Engl J Med. 1986;314(9):541–7.Google Scholar

Patel, KP, O’Brien, TW, Subramony, SH, Shuster, J, Stacpoole, PW. The spectrum of pyruvate dehydrogenase complex deficiency: Clinical, biochemical and genetic features in 371 patients. Mol Genet Metab. 2012;106(3):385–94.Google Scholar

Debray, FG, Lambert, M, Gagne, R, et al. Pyruvate dehydrogenase deficiency presenting as intermittent isolated acute ataxia. Neuropediatrics. 2008;39(1):20–3.Google Scholar

Marin-Valencia, I, Roe, CR, Pascual, JM. Pyruvate carboxylase deficiency: Mechanisms, mimics and anaplerosis. Mol Genet Metab. 2010;101(1):9–17.Google Scholar

Sofou, K, de Coo, IFM, Ostergaard, E, et al. Phenotype–genotype correlations in Leigh syndrome: New insights from a multicentre study of 96 patients. J Med Genet. 2018;55(1):21–7.Google Scholar

Wolf, B. Biotinidase deficiency. GeneReviews®. 2000;Mar 24 (updated Jun 9, 2016).Google Scholar

Wolf, B. “Think metabolic” in adults with diagnostic challenges: Biotinidase deficiency as a paradigm disorder. Neurol Clin Pract. 2017;7(6):518–22.Google Scholar

Tabarki, B, Al-Shafi, S, Al-Shahwan, S, et al. Biotin-responsive basal ganglia disease revisited: Clinical, radiologic, and genetic findings. Neurology. 2013;80(3):261–7.CrossRef Google Scholar PubMed

Leen, WG, Klepper, J, Verbeek, MM, et al. Glucose transporter-1 deficiency syndrome: The expanding clinical and genetic spectrum of a treatable disorder. Brain. 2010;133(Pt 3):655–70.CrossRef Google Scholar PubMed

Leen, WG, Mewasingh, L, Verbeek, MM, et al. Movement disorders in GLUT1 deficiency syndrome respond to the modified Atkins diet. Mov Disord. 2013;28(10):1439–42.Google Scholar

Verrips, A, van Engelen, BG, Wevers, RA, et al. Presence of diarrhea and absence of tendon xanthomas in patients with cerebrotendinous xanthomatosis. Arch Neurol. 2000;57(4):520–4.Google Scholar

Yahalom, G, Tsabari, R, Molshatzki, N, et al. Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: Early versus late diagnosis. Clin Neuropharmacol. 2013;36(3):78–83.Google Scholar

Hentati, F, El-Euch, G, Bouhlal, Y, Amouri, R. Ataxia with vitamin E deficiency and abetalipoproteinemia. Handb Clin Neurol. 2012;103:295–305.Google Scholar

Seo, GH, Kim, YM, Oh, SH, et al. Biochemical and molecular characterisation of neurological Wilson disease. J Med Genet. 2018;55(9):587–93.Google Scholar

Bandmann, O, Weiss, KH, Kaler, SG. Wilson’s disease and other neurological copper disorders. Lancet Neurol. 2015;14(1):103–13.Google Scholar

Vroegindeweij, LHP, Langendonk, JG, Langeveld, M, et al. New insights in the neurological phenotype of aceruloplasminemia in Caucasian patients. Parkinsonism Relat Disord. 2017;36:33–40.Google Scholar

Poli, L, Alberici, A, Buzzi, P, Marchina, E, Lanari, A, Arosio, C, et al. Is aceruloplasminemia treatable? Combining iron chelation and fresh-frozen plasma treatment. Neurol Sci. 2017;38(2):357–60.Google Scholar

Wanders, RJA, Waterham, HR, Leroy, BP. Refsum disease. GeneReviews®. 2006;Mar 20 (updated Jun 11, 2015).Google Scholar

Patterson, MC, Mengel, E, Wijburg, FA, et al. Disease and patient characteristics in NP-C patients: Findings from an international disease registry. Orphanet J Rare Dis. 2013;8:12.Google Scholar

Emmanuele, V, Lopez, LC, Berardo, A, et al. Heterogeneity of coenzyme Q10 deficiency: Patient study and literature review. Arch Neurol. 2012;69(8):978–83.Google Scholar

Balreira, A, Boczonadi, V, Barca, E, et al. ANO10 mutations cause ataxia and coenzyme Q(1)(0) deficiency. J Neurol. 2014;261(11):2192–8.Google Scholar

Raymond, GV, Moser, AB, Fatemi, A. X-linked adrenoleukodystrophy. GeneReviews®. 1999;Mar 26 (updated Feb 15, 2018).Google Scholar

Mahmood, A, Berry, J, Wenger, DA, et al. Metachromatic leukodystrophy: A case of triplets with the late infantile variant and a systematic review of the literature. J Child Neurol. 2010;25(5):572–80.Google Scholar

Sedel, F, Tourbah, A, Fontaine, B, et al. Leukoencephalopathies associated with inborn errors of metabolism in adults. J Inherit Metab Dis. 2008;31(3):295–307.Google Scholar

Kwon, JM, Matern, D, Kurtzberg, J, et al. Consensus guidelines for newborn screening, diagnosis and treatment of infantile Krabbe disease. Orphanet J Rare Dis. 2018;13:30.Google Scholar

Malm, D, Nilssen, O. Alpha-mannosidosis. Orphanet J Rare Dis. 2008;3:21.Google Scholar

Mercimek-Mahmutogly, S, Salamons, GS. Creatine deficiency syndromes. GeneReviews®. 2009;Jan 15 (updated Dec 10, 2015).Google Scholar

Hyland, K, Shoffner, J, Heales, SJ. Cerebral folate deficiency. J Inherit Metab Dis. 2010;33(5):563–70.Google Scholar

Synofzik, M, Srulijes, K, Godau, J, Berg, D, Schols, L. Characterizing POLG ataxia: Clinics, electrophysiology and imaging. Cerebellum. 2012;11(4):1002–11.Google Scholar

Steenweg, ME, Jakobs, C, Errami, A, et al. An overview of L-2-hydroxyglutarate dehydrogenase gene (L2HGDH) variants: A genotype–phenotype study. Hum Mutat. 2010;31(4):380–90.Google Scholar

Miossec-Chauvet, E, Mikaeloff, Y, Heron, D, et al. Neurological presentation in pediatric patients with congenital disorders of glycosylation type Ia. Neuropediatrics. 2003;34(1):1–6.Google Scholar

Drouin-Garraud, V, Belgrand, M, Grunewald, S, et al. Neurological presentation of a congenital disorder of glycosylation CDG-Ia: Implications for diagnosis and genetic counseling. Am J Med Genet. 2001;101(1):46–9.Google Scholar

Maegawa, GH, Stockley, T, Tropak, M, et al. The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported. Pediatrics. 2006;118(5):e1550-62.Google Scholar

Thorburn, DR, Rahman, J, Rahman, S. Mitochondrial DNA-associated Leigh syndrome and NARP. GeneReviews®. 2003;Oct 30 (updated Sep 28, 2017).Google Scholar

Craig, K, Elliott, HR, Keers, SM, et al. Episodic ataxia and hemiplegia caused by the 8993 T→C mitochondrial DNA mutation. J Med Genet. 2007;44(12):797–9.Google Scholar

Yamashita, T, Mitsui, J, Shimozawa, N, et al. Ataxic form of autosomal recessive PEX10-related peroxisome biogenesis disorders with a novel compound heterozygous gene mutation and characteristic clinical phenotype. J Neurol Sci. 2017;375:424–9.Google Scholar

Lapalme-Remis, S, Lewis, EC, De Meulemeester, C, et al. Natural history of succinic semialdehyde dehydrogenase deficiency through adulthood. Neurology. 2015;85(10):861–5.Google Scholar

Pearl, PL, Wiwattanadittakul, N, Roullet, JB, Gibson, KM. Succinic semialdehyde dehydrogenase deficiency. GeneReviews®. 2004;May 5 (updated Apr 28, 2016).Google Scholar

van der Veen, S, Zutt, R, Elting, JWJ, et al. Progressive myoclonus ataxia: Time for a new definition? Mov Disord. 2018;33(8):1281–6.Google Scholar

Seyrantepe, V, Poupetova, H, Froissart, R, et al. Molecular pathology of NEU1 gene in sialidosis. Hum Mutat. 2003;22(5):343–52.Google Scholar

Turnbull, J, Tiberia, E, Striano, P, et al. Lafora disease. Epileptic Disord. 2016;18(S2):38–62.Google Scholar

DiMauro, S, Hirano, M. MERRF. GeneReviews®. 2003;Jun 3 (updated Jan 29, 2015).Google Scholar

Mancini, C, Nassani, S, Guo, Y, et al. Adult-onset autosomal recessive ataxia associated with neuronal ceroid lipofuscinosis type 5 gene (CLN5) mutations. J Neurol. 2015;262(1):173–8.Google Scholar

Roshan Lal, T, Sidransky, E. The spectrum of neurological manifestations associated with Gaucher disease. Diseases. 2017;5(1).Google Scholar

Garcia-Cazorla, A, Wolf, NI, Serrano, M, et al. Inborn errors of metabolism and motor disturbances in children. J Inherit Metab Dis. 2009;32(5):618–29.Google Scholar

Eggink, H, Kuiper, A, Peall, KJ, et al. Rare inborn errors of metabolism with movement disorders: A case study to evaluate the impact upon quality of life and adaptive functioning. Orphanet J Rare Dis. 2014;9:177.Google Scholar

Albanese, A, Bhatia, K, Bressman, SB, et al. Phenomenology and classification of dystonia: A consensus update. Mov Disord. 2013;28(7):863–73.Google Scholar

Lehericy, S, Tijssen, MA, Vidailhet, M, Kaji, R, Meunier, S. The anatomical basis of dystonia: Current view using neuroimaging. Mov Disord. 2013;28(7):944–57.Google Scholar

Steeves, TD, Day, L, Dykeman, J, Jette, N, Pringsheim, T. The prevalence of primary dystonia: A systematic review and meta-analysis. Mov Disord. 2012;27(14):1789–96.Google Scholar

Gouider-Khouja, N, Kraoua, I, Benrhouma, H, Fraj, N, Rouissi, A. Movement disorders in neuro-metabolic diseases. Eur J Paediatr Neurol. 2010;14(4):304–7.Google Scholar

Fung, VS, Jinnah, HA, Bhatia, K, Vidailhet, M. Assessment of patients with isolated or combined dystonia: An update on dystonia syndromes. Mov Disord. 2013;28(7):889–98.Google Scholar

van Egmond, ME, Kuiper, A, Eggink, H, et al. Dystonia in children and adolescents: A systematic review and a new diagnostic algorithm. J Neurol Neurosurg Psychiatry. 2015;86(7):774–81.Google Scholar

Kuiper, MJ, Brandsma, R, Vrijenhoek, L, et al. Physiological movement disorder-like features during typical motor development. Eur J Paediatr Neurol. 2018;22(4):595–601.Google Scholar

Rosenbaum, P, Paneth, N, Leviton, A, et al. A report: The definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl. 2007;109:8–14.Google Scholar

Bax, M, Tydeman, C, Flodmark, O. Clinical and MRI correlates of cerebral palsy: The European Cerebral Palsy Study. JAMA. 2006;296(13):1602–8.Google Scholar

Schneider, SA, Bhatia, KP. Secondary dystonia: Clinical clues and syndromic associations. Eur J Neurol. 2010;17 Suppl 1:52–7.Google Scholar

Kuiper, A, Eggink, H, Tijssen, MA, de Koning, TJ. Neurometabolic disorders are treatable causes of dystonia. Rev Neurol (Paris). 2016;172(8–9):455–64.Google Scholar

van Egmond, ME, Eggink, H, Kuiper, A, et al. Crossing barriers: A multidisciplinary approach to children and adults with young-onset movement disorders. J Clin Mov Disord. 2018;5:3.Google Scholar

Maas, R, Wassenberg, T, Lin, JP, van de Warrenburg, BPC, Willemsen, M. L-dopa in dystonia: A modern perspective. Neurology. 2017;88(19):1865–71.Google Scholar

Koy, A, Lin, JP, Sanger, TD, et al. Advances in management of movement disorders in children. Lancet Neurol. 2016;15(7):719–35.Google Scholar

van Egmond, ME, Lugtenberg, CHA, Brouwer, OF, et al. A post hoc study on gene panel analysis for the diagnosis of dystonia. Mov Disord. 2017;32(4):569–75.Google Scholar

Hennekam, RC, Biesecker, LG. Next-generation sequencing demands next-generation phenotyping. Hum Mutat. 2012;33(5):884–6.Google Scholar

Ng, J, Papandreou, A, Heales, SJ, Kurian, MA. Monoamine neurotransmitter disorders: Clinical advances and future perspectives. Nat Rev Neurol. 2015;11(10):567–84.Google Scholar

Lee, WW, Jeon, BS. Clinical spectrum of dopa-responsive dystonia and related disorders. Curr Neurol Neurosci Rep. 2014;14(7):461.Google Scholar

Taly, AB, Meenakshi-Sundaram, S, Sinha, S, Swamy, HS, Arunodaya, GR. Wilson disease: Description of 282 patients evaluated over 3 decades. Medicine (Baltimore). 2007;86(2):112–21.Google Scholar

Stamelou, M, Tuschl, K, Chong, WK, et al. Dystonia with brain manganese accumulation resulting from SLC30A10 mutations: A new treatable disorder. Mov Disord. 2012;27(10):1317–22.Google Scholar

Schneider, SA, Bhatia, KP. Rare causes of dystonia parkinsonism. Curr Neurol Neurosci Rep. 2010;10(6):431–9.Google Scholar

Viau, K, Ernst, SL, Vanzo, RJ, et al. Glutaric acidemia type 1: Outcomes before and after expanded newborn screening. Mol Genet Metab. 2012;106(4):430–8.Google Scholar

Dionisi-Vici, C, Deodato, F, Roschinger, W, Rhead, W, Wilcken, B. ‘Classical’ organic acidurias, propionic aciduria, methylmalonic aciduria and isovaleric aciduria: Long-term outcome and effects of expanded newborn screening using tandem mass spectrometry. J Inherit Metab Dis. 2006;29(2–3):383–9.Google Scholar

Koens, LH, Kuiper, A, Coenen, MA, et al. Ataxia, dystonia and myoclonus in adult patients with Niemann–Pick type C. Orphanet J Rare Dis. 2016;11:121.Google Scholar

Patterson, MC, Hendriksz, CJ, Walterfang, M, et al. Recommendations for the diagnosis and management of Niemann–Pick disease type C: An update. Mol Genet Metab. 2012;106(3):330–44.Google Scholar

Roze, E, Paschke, E, Lopez, N, et al. Dystonia and parkinsonism in GM1 type 3 gangliosidosis. Mov Disord. 2005;20(10):1366–9.Google Scholar

Gautschi, M, Merlini, L, Calza, AM, et al. Late diagnosis of fucosidosis in a child with progressive fixed dystonia, bilateral pallidal lesions and red spots on the skin. Eur J Paediatr Neurol. 2014;18(4):516–9.Google Scholar

Martikainen, MH, Ng, YS, Gorman, GS, et al. Clinical, genetic, and radiological features of extrapyramidal movement disorders in mitochondrial disease. JAMA Neurol. 2016;73(6):668–74.Google Scholar

Rahman, S, Thorburn, D. Nuclear gene-encoded Leigh syndrome overview. GeneReviews®. 2015; Oct 1.Google Scholar

Ortigoza-Escobar, JD, Molero-Luis, M, Arias, A, et al. Free-thiamine is a potential biomarker of thiamine transporter-2 deficiency: A treatable cause of Leigh syndrome. Brain. 2016;139(Pt 1):31–8.Google Scholar

Synofzik, M, Srulijes, K, Godau, J, Berg, D, Schols, L. Characterizing POLG ataxia: Clinics, electrophysiology and imaging. Cerebellum. 2012;11(4):1002–11.Google Scholar

Barnerias, C, Saudubray, JM, Touati, G, et al. Pyruvate dehydrogenase complex deficiency: Four neurological phenotypes with differing pathogenesis. Dev Med Child Neurol. 2010;52(2):e1–9.Google Scholar

Pearson, TS, Akman, C, Hinton, VJ, Engelstad, K, De Vivo, DC. Phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS). Curr Neurol Neurosci Rep. 2013;13(4):342.Google Scholar

van de Kamp, JM, Mancini, GM, Salomons, GS. X-linked creatine transporter deficiency: Clinical aspects and pathophysiology. J Inherit Metab Dis. 2014;37(5):715–33.Google Scholar

Lagarde, J, Roze, E, Apartis, E, Pothalil, D, Sedel, F, Couvert, P, et al. Myoclonus and dystonia in cerebrotendinous xanthomatosis. Mov Disord. 2012;27(14):1805–10.Google Scholar

Rubio-Agusti, I, Carecchio, M, Bhatia, KP, et al. Movement disorders in adult patients with classical galactosemia. Mov Disord. 2013;28(6):804–10.Google Scholar

Peall, KJ, Kuiper, A, de Koning, TJ, Tijssen, MA. Non-motor symptoms in genetically defined dystonia: Homogenous groups require systematic assessment. Parkinsonism Relat Disord. 2015;21(9):1031–40.Google Scholar

Timmers, ER, Kuiper, A, Smit, M, et al. Non-motor symptoms and quality of life in dopa-responsive dystonia patients. Parkinsonism Relat Disord. 2017;45:57–62.Google Scholar

Balash, Y, Giladi, N. Efficacy of pharmacological treatment of dystonia: Evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. Eur J Neurol. 2004;11(6):361–70.Google Scholar

Liow, NY, Gimeno, H, Lumsden, DE, et al. Gabapentin can significantly improve dystonia severity and quality of life in children. Eur J Paediatr Neurol. 2016;20(1):100–7.Google Scholar

Sayer, C, Lumsden, DE, Kaminska, M, Lin, JP. Clonidine use in the outpatient management of severe secondary dystonia. Eur J Paediatr Neurol. 2017;21(4):621–6.Google Scholar

Mink, JW. Treatment of paroxysmal dyskinesias in children. Curr Treat Options Neurol. 2015;17(6):350.Google Scholar

Jankovic, J. Medical treatment of dystonia. Mov Disord. 2013;28(7):1001–12.Google Scholar

Jinnah, HA, Alterman, R, Klein, C, et al. Deep brain stimulation for dystonia: A novel perspective on the value of genetic testing. J Neural Transm (Vienna). 2017;124(4):417–30.Google Scholar

Ge, M, Zhang, K, Ma, Y, et al. Bilateral subthalamic nucleus stimulation in the treatment of neurodegeneration with brain iron accumulation type 1. Stereotact Funct Neurosurg. 2011;89(3):162–6.Google Scholar

Lumsden, DE, Gimeno, H, Tustin, K, Kaminska, M, Lin, JP. Interventional studies in childhood dystonia do not address the concerns of children and their carers. Eur J Paediatr Neurol. 2015;19(3):327–36.Google Scholar

Lumsden, DE, Allen, NM. Rethinking status dystonicus: A welcome start to a challenging problem. Mov Disord. 2018;33(2):344.Google Scholar

Lumsden, DE, King, MD, Allen, NM. Status dystonicus in childhood. Curr Opin Pediatr. 2017;29(6):674–82.Google Scholar

Fahn, S, Jankovic, J, Hallett, M. Principles and Practice of Movement Disorders, 2nd edn. Philadelphia, PA: Elsevier; 2011.Google Scholar

Postuma, RB, Berg, D, Stern, M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–601.Google Scholar

Kang, SY, Wasaka, T, Shamim, EA, et al. Characteristics of the sequence effect in Parkinson’s disease. Mov Disord. 2010;25(13):2148–55.Google Scholar

Golbe, LI. Young-onset Parkinson’s disease: A clinical review. Neurology. 1991;41(2(Pt 1)):168–73.Google Scholar

Quinn, N, Critchley, P, Marsden, CD. Young onset Parkinson’s disease. Mov Disord. 1987;2(2):73–91.Google Scholar

Paviour, DC, Surtees, RA, Lees, AJ. Diagnostic considerations in juvenile parkinsonism. Mov Disord. 2004;19(2):123–35.Google Scholar

Correia Guedes, L, Ferreira, JJ, Rosa, MM, et al. Worldwide frequency of G2019S LRRK2 mutation in Parkinson’s disease: A systematic review. Parkinsonism Relat Disord. 2010;16(4):237–42.Google Scholar

Schneider, SA, Alcalay, RN. Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature. Mov Disord. 2017;32(11):1504–23.Google Scholar

Mandemakers, W, Quadri, M, Stamelou, M, Bonifati, V. TMEM230: How does it fit in the etiology and pathogenesis of Parkinson’s disease? Mov Disord. 2017;32(8):1159–62.Google Scholar

Kumaran, R, Cookson, MR. Pathways to Parkinsonism redux: Convergent pathobiological mechanisms in genetics of Parkinson’s disease. Hum Mol Genet. 2015;24(R1):R32–44.Google Scholar

Garcia-Cazorla, A, Duarte, ST. Parkinsonism and inborn errors of metabolism. J Inherit Metab Dis. 2014;37(4):627–42.Google Scholar

Schrag, A, Schott, JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol. 2006;5(4):355–63.Google Scholar

Fernandez-Alvarez, E. Frequency of movement disorders in children. Rev Neurol. 2001;33(3):228–9.Google Scholar

Fernandez-Alvarez, E, Aicardi, J. Movement Disorders in Children. London: Mac Keith Press; 2001.Google Scholar

Garcia-Cazorla, A, Ortez, C, Perez-Duenas, B, et al. Hypokinetic–rigid syndrome in children and inborn errors of metabolism. Eur J Paediatr Neurol. 2011;15(4):295–302.Google Scholar

Kurian, MA, Gissen, P, Smith, M, Heales, S, Jr., Clayton, PT. The monoamine neurotransmitter disorders: An expanding range of neurological syndromes. Lancet Neurol. 2011;10(8):721–33.Google Scholar

Ng, J, Papandreou, A, Heales, SJ, Kurian, MA. Monoamine neurotransmitter disorders: Clinical advances and future perspectives. Nat Rev Neurol. 2015;11(10):567–84.Google Scholar

Rodan, LH, Gibson, KM, Pearl, PL. Clinical use of CSF neurotransmitters. Pediatr Neurol. 2015;53(4):277–86.Google Scholar

Wijemanne, S, Jankovic, J. Dopa-responsive dystonia: Clinical and genetic heterogeneity. Nat Rev Neurol. 2015;11(7):414–24.Google Scholar

Rilstone, JJ, Alkhater, RA, Minassian, BA. Brain dopamine–serotonin vesicular transport disease and its treatment. N Engl J Med. 2013;368(6):543–50.Google Scholar

Brun, L, Ngu, LH, Keng, WT, et al. Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology. 2010;75(1):64–71.Google Scholar

Segawa, M, Nomura, Y, Nishiyama, N. Autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease). Ann Neurol. 2003;54 Suppl 6:S32–45.Google Scholar

Furukawa, Y, Kish, SJ, Bebin, EM, et al. Dystonia with motor delay in compound heterozygotes for GTP-cyclohydrolase I gene mutations. Ann Neurol. 1998;44(1):10–6.Google Scholar

Opladen, T, Hoffmann, G, Horster, F, et al. Clinical and biochemical characterization of patients with early infantile onset of autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia. Mov Disord. 2011;26(1):157–61.Google Scholar

Friedman, J, Roze, E, Abdenur, JE, et al. Sepiapterin reductase deficiency: A treatable mimic of cerebral palsy. Ann Neurol. 2012;71(4):520–30.Google Scholar

Opladen, T, Hoffmann, GF, Blau, N. An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia. J Inherit Metab Dis. 2012;35(6):963–73.Google Scholar

Takahashi, Y, Manabe, Y, Nakano, Y, et al. Parkinsonism in association with dihydropteridine reductase deficiency. Case Rep Neurol. 2017;9(1):17–21.Google Scholar

Willemsen, MA, Verbeek, MM, Kamsteeg, EJ, et al. Tyrosine hydroxylase deficiency: A treatable disorder of brain catecholamine biosynthesis. Brain. 2010;133(Pt 6):1810–22.Google Scholar

Hoffmann, GF, Assmann, B, Brautigam, C, et al. Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia. Ann Neurol. 2003;54 Suppl 6:S56–65.Google Scholar

Pons, R, Syrengelas, D, Youroukos, S, et al. Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency. Mov Disord. 2013;28(8):1058–63.Google Scholar

Chien, YH, Lee, NC, Tseng, SH, et al. Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: An open-label, phase 1/2 trial. Lancet Child Adolesc Health. 2017;1(4):265–73.Google Scholar

Jacobsen, JC, Wilson, C, Cunningham, V, et al. Brain dopamine–serotonin vesicular transport disease presenting as a severe infantile hypotonic parkinsonian disorder. J Inherit Metab Dis. 2016;39(2):305–8.Google Scholar

Saito, T. Presenting symptoms and natural history of Wilson disease. Eur J Pediatr. 1987;146(3):261–5.Google Scholar

Czlonkowska, A, Litwin, T, Chabik, G. Wilson disease: Neurologic features. Handb Clin Neurol. 2017;142:101–19.Google Scholar

Machado, A, Chien, HF, Deguti, MM, et al. Neurological manifestations in Wilson’s disease: Report of 119 cases. Mov Disord. 2006;21(12):2192–6.Google Scholar

Hayflick, SJ, Kurian, MA, Hogarth, P. Neurodegeneration with brain iron accumulation. Handb Clin Neurol. 2018;147:293–305.Google Scholar

Hogarth, P, Gregory, A, Kruer, MC, et al. New NBIA subtype: Genetic, clinical, pathologic, and radiographic features of MPAN. Neurology. 2013;80(3):268–75.Google Scholar

Hayflick, SJ, Kruer, MC, Gregory, A, et al. Beta-propeller protein-associated neurodegeneration: A new X-linked dominant disorder with brain iron accumulation. Brain. 2013;136(Pt 6):1708–17.Google Scholar

Costello, DJ, Walsh, SL, Harrington, HJ, Walsh, CH. Concurrent hereditary haemochromatosis and idiopathic Parkinson’s disease: A case report series. J Neurol Neurosurg Psychiatry. 2004;75(4):631–3.Google Scholar

Sedel, F, Saudubray, JM, Roze, E, Agid, Y, Vidailhet, M. Movement disorders and inborn errors of metabolism in adults: A diagnostic approach. J Inherit Metab Dis. 2008;31(3):308–18.Google Scholar

Marti-Sanchez, L, Ortigoza-Escobar, JD, Darling, A, et al. Hypermanganesemia due to mutations in SLC39A14: Further insights into Mn deposition in the central nervous system. Orphanet J Rare Dis. 2018;13:28.Google Scholar

Tuschl, K, Meyer, E, Valdivia, LE, et al. Mutations in SLC39A14 disrupt manganese homeostasis and cause childhood-onset parkinsonism–dystonia. Nat Commun. 2016;7:11601.Google Scholar

Tuschl, K, Clayton, PT, Gospe, SM, Jr., et al. Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man. Am J Hum Genet. 2016;99(2):521.Google Scholar

Ebrahimi-Fakhari, D, Hildebrandt, C, Davis, PE, et al. The spectrum of movement disorders in childhood-onset lysosomal storage diseases. Mov Disord Clin Pract. 2018;5(2):149–55.Google Scholar

Dehay, B, Martinez-Vicente, M, Caldwell, GA, et al. Lysosomal impairment in Parkinson’s disease. Mov Disord. 2013;28(6):725–32.Google Scholar

Liu, JP, Tang, Y, Zhou, S, et al. Cholesterol involvement in the pathogenesis of neurodegenerative diseases. Mol Cell Neurosci. 2010;43(1):33–42.Google Scholar

Kraoua, I, Stirnemann, J, Ribeiro, MJ, et al. Parkinsonism in Gaucher’s disease type 1: Ten new cases and a review of the literature. Mov Disord. 2009;24(10):1524–30.Google Scholar

Hendriksz, CJ, Anheim, M, Bauer, P, et al. The hidden Niemann–Pick type C patient: Clinical niches for a rare inherited metabolic disease. Curr Med Res Opin. 2017;33(5):877–90.Google Scholar

Coleman, RJ, Robb, SA, Lake, BD, Brett, EM, Harding, AE. The diverse neurological features of Niemann–Pick disease type C: A report of two cases. Mov Disord. 1988;3(4):295–9.Google Scholar

Mole, SE, Williams, RE. Neuronal ceroid-lipofuscinoses. GeneReviews®. 2001;Oct 10 (updated Aug 1, 2013).Google Scholar

Bras, J, Verloes, A, Schneider, SA, Mole, SE, Guerreiro, RJ. Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis. Hum Mol Genet. 2012;21(12):2646–50.CrossRef Google Scholar PubMed

Mink, JW, Augustine, EF, Adams, HR, Marshall, FJ, Kwon, JM. Classification and natural history of the neuronal ceroid lipofuscinoses. J Child Neurol. 2013;28(9):1101–5.Google Scholar

Behrens, MI, Bruggemann, N, Chana, P, et al. Clinical spectrum of Kufor–Rakeb syndrome in the Chilean kindred with ATP13A2 mutations. Mov Disord. 2010;25(12):1929–37.Google Scholar

Roze, E, Paschke, E, Lopez, N, et al. Dystonia and parkinsonism in GM1 type 3 gangliosidosis. Mov Disord. 2005;20(10):1366–9.Google Scholar

Gravel, RA, Kaback, MM, Proia, RL, et al. The GM2 gangliosidoses. In Beaudet, AL, Vogelstein, B, Kinzler, KW, et al., editors. The Online Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2014. [Online, accessed Dec 1, 2019;doi:10.1036/ommbid.184.]Google Scholar

Inzelberg, R, Korczyn, AD. Parkinsonism in adult-onset GM2 gangliosidosis. Mov Disord. 1994;9(3):375–7.Google Scholar

Silveira-Moriyama, L, Moriyama, TS, Gabbi, TV, Ranvaud, R, Barbosa, ER. Chédiak–Higashi syndrome with parkinsonism. Mov Disord. 2004;19(4):472–5.Google Scholar

Hara, M, Inokuchi, T, Taniwaki, T, et al. An adult patient with mucolipidosis III alpha/beta presenting with parkinsonism. Brain Dev. 2013;35(5):462–5.Google Scholar

Finsterer, J. Parkinson’s syndrome and Parkinson’s disease in mitochondrial disorders. Mov Disord. 2011;26(5):784–91.Google Scholar

Martikainen, MH, Ng, YS, Gorman, GS, et al. Clinical, genetic, and radiological features of extrapyramidal movement disorders in mitochondrial disease. JAMA Neurol. 2016;73(6):668–74.Google Scholar

Ghaoui, R, Sue, CM. Movement disorders in mitochondrial disease. J Neurol. 2018;265(5):1230–40.Google Scholar

Luoma, PT, Eerola, J, Ahola, S, et al. Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease. Neurology. 2007;69(11):1152–9.Google Scholar

Luoma, P, Melberg, A, Rinne, JO, et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: Clinical and molecular genetic study. Lancet. 2004;364(9437):875–82.Google Scholar

Garcia-Cazorla, A, Rabier, D, Touati, G, et al. Pyruvate carboxylase deficiency: Metabolic characteristics and new neurological aspects. Ann Neurol. 2006;59(1):121–7.Google Scholar

Sakaue, S, Kasai, T, Mizuta, I, et al. Early-onset parkinsonism in a pedigree with phosphoglycerate kinase deficiency and a heterozygous carrier: Do PGK-1 mutations contribute to vulnerability to parkinsonism? NPJ Parkinsons Dis. 2017;3:13.Google Scholar

Sotiriou, E, Greene, P, Krishna, S, Hirano, M, DiMauro, S. Myopathy and parkinsonism in phosphoglycerate kinase deficiency. Muscle Nerve. 2010;41(5):707–10.Google Scholar

Pons, R, Collins, A, Rotstein, M, Engelstad, K, De Vivo, DC. The spectrum of movement disorders in Glut-1 deficiency. Mov Disord. 2010;25(3):275–81.Google Scholar

Tabarki, B, Al-Shafi, S, Al-Shahwan, S, et al. Biotin-responsive basal ganglia disease revisited: Clinical, radiologic, and genetic findings. Neurology. 2013;80(3):261–7.Google Scholar

Ozand, PT, Gascon, GG, Al Essa, M, et al. Biotin-responsive basal ganglia disease: A novel entity. Brain. 1998;121 (Pt 7):1267–79.Google Scholar

Kikuchi, K, Hamano, S, Mochizuki, H, Ichida, K, Ida, H. Molybdenum cofactor deficiency mimics cerebral palsy: Differentiating factors for diagnosis. Pediatr Neurol. 2012;47(2):147–9.Google Scholar

Alkufri, F, Harrower, T, Rahman, Y, et al. Molybdenum cofactor deficiency presenting with a parkinsonism–dystonia syndrome. Mov Disord. 2013;28(3):399–401.Google Scholar

Nie, S, Chen, G, Cao, X, Zhang, Y. Cerebrotendinous xanthomatosis: A comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphanet J Rare Dis. 2014;9:179.Google Scholar

Federico, A, Dotti, MT, Gallus, GN. Cerebrotendinous xanthomatosis. GeneReviews®. 2003; Jul 16 (updated Apr 14, 2016).Google Scholar

Su, CS, Chang, WN, Huang, SH, et al. Cerebrotendinous xanthomatosis patients with and without parkinsonism: Clinical characteristics and neuroimaging findings. Mov Disord. 2010;25(4):452–8.Google Scholar

Gitiaux, C, Roze, E, Kinugawa, K, et al. Spectrum of movement disorders associated with glutaric aciduria type 1: A study of 16 patients. Mov Disord. 2008;23(16):2392–7.Google Scholar

Gascon, GG, Ozand, PT, Brismar, J. Movement disorders in childhood organic acidurias. Clinical, neuroimaging, and biochemical correlations. Brain Dev. 1994;16 Suppl:94–103.Google Scholar

Sinclair, AJ, Barling, L, Nightingale, S. Recurrent dystonia in homocystinuria: A metabolic pathogenesis. Mov Disord. 2006;21(10):1780–2.Google Scholar

Ekinci, B, Apaydin, H, Vural, M, Ozekmekci, S. Two siblings with homocystinuria presenting with dystonia and parkinsonism. Mov Disord. 2004;19(8):962–4.Google Scholar

Ramos, EM, Carecchio, M, Lemos, R, et al. Primary brain calcification: An international study reporting novel variants and associated phenotypes. Eur J Hum Genet. 2018;26(10):1462–77.Google Scholar

Batla, A, Tai, XY, Schottlaender, L, et al. Deconstructing Fahr’s disease/syndrome of brain calcification in the era of new genes. Parkinsonism Relat Disord. 2017;37:1–10.Google Scholar

Manyam, BV, Walters, AS, Keller, IA, Ghobrial, M. Parkinsonism associated with autosomal dominant bilateral striopallidodentate calcinosis. Parkinsonism Relat Disord. 2001;7(4):289–95.Google Scholar

Ramos, EM, Oliveira, JR, Sobrido, MJ, Coppola, G. Primary familial brain calcification. GeneReviews®. 2004;Apr 18 (updated Aug 24, 2017).Google Scholar

Sedel, F, Fontaine, B, Saudubray, JM, Lyon-Caen, O. Hereditary spastic paraparesis in adults associated with inborn errors of metabolism: A diagnostic approach. J Inherit Metab Dis. 2007;30(6):855–64.Google Scholar

Martinelli, D, Diodato, D, Ponzi, E, et al. The hyperornithinemia–hyperammonemia–homocitrullinuria syndrome. Orphanet J Rare Dis. 2015;10:29.Google Scholar

Huemer, M, Diodato, D, Schwahn, B, et al. Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. J Inherit Metab Dis. 2017;40(1):21–48.Google Scholar

Wolf, B. The neurology of biotinidase deficiency. Mol Genet Metab. 2011;104(1–2):27–34.Google Scholar

Chedrawi, AK, Ali, A, Al Hassnan, ZN, Faiyaz-Ul-Haque, M, Wolf, B. Profound biotinidase deficiency in a child with predominantly spinal cord disease. J Child Neurol. 2008;23(9):1043–8.Google Scholar

Ramaekers, VT, Brab, M, Rau, G, Heimann, G. Recovery from neurological deficits following biotin treatment in a biotinidase Km variant. Neuropediatrics. 1993;24(2):98–102.Google Scholar

Ramaekers, V, Sequeira, JM, Quadros, EV. Clinical recognition and aspects of the cerebral folate deficiency syndromes. Clin Chem Lab Med. 2013;51(3):497–511.Google Scholar

Federico, A, Dotti, MT, Gallus, GN. Cerebrotendinous xanthomatosis. GeneReviews®. 2003;Jul 16 (updated Apr 14, 2016).Google Scholar

Wong, JC, Walsh, K, Hayden, D, Eichler, FS. Natural history of neurological abnormalities in cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2018;41(4):647–56.Google Scholar

Abe, R, Sekijima, Y, Kinoshita, T, et al. Spinal form cerebrotendinous xanthomatosis patient with long spinal cord lesion. J Spinal Cord Med. 2016;39(6):726–9.Google Scholar

McCombe, PA, McLaughlin, DB, Chalk, JB, et al. Spasticity and white matter abnormalities in adult phenylketonuria. J Neurol Neurosurg Psychiatry. 1992;55(5):359–61.Google Scholar

Atwal, PS, Scaglia, F. Molybdenum cofactor deficiency. Mol Genet Metab. 2016;117(1):1–4.Google Scholar

Duffner, PK, Barczykowski, A, Jalal, K, et al. Early infantile Krabbe disease: Results of the World-Wide Krabbe Registry. Pediatr Neurol. 2011;45(3):141–8.Google Scholar

Duffner, PK, Jalal, K, Carter, RL. The Hunter’s Hope Krabbe family database. Pediatr Neurol. 2009;40(1):13–8.Google Scholar

Abdelhalim, AN, Alberico, RA, Barczykowski, AL, Duffner, PK. Patterns of magnetic resonance imaging abnormalities in symptomatic patients with Krabbe disease correspond to phenotype. Pediatr Neurol. 2014;50(2):127–34.Google Scholar

Husain, AM, Altuwaijri, M, Aldosari, M. Krabbe disease: Neurophysiologic studies and MRI correlations. Neurology. 2004;63(4):617–20.Google Scholar

Wright, MD, Poe, MD, DeRenzo, A, Haldal, S, Escolar, ML. Developmental outcomes of cord blood transplantation for Krabbe disease: A 15-year study. Neurology. 2017;89(13):1365–72.Google Scholar

Mahmood, A, Berry, J, Wenger, DA, Escolar, M, Sobeih, M, Raymond, G, et al. Metachromatic leukodystrophy: A case of triplets with the late infantile variant and a systematic review of the literature. J Child Neurol. 2010;25(5):572–80.Google Scholar

Cameron, CL, Kang, PB, Burns, TM, Darras, BT, Jones, HR, Jr. Multifocal slowing of nerve conduction in metachromatic leukodystrophy. Muscle Nerve. 2004;29(4):531–6.Google Scholar

Eichler, F, Grodd, W, Grant, E, et al. Metachromatic leukodystrophy: A scoring system for brain MR imaging observations. AJNR Am J Neuroradiol. 2009;30(10):1893–7.Google Scholar

van Rappard, DF, Bugiani, M, Boelens, JJ, et al. Gallbladder and the risk of polyps and carcinoma in metachromatic leukodystrophy. Neurology. 2016;87(1):103–11.Google Scholar

Groeschel, S, Kuhl, JS, Bley, AE, et al. Long-term outcome of allogeneic hematopoietic stem cell transplantation in patients with juvenile metachromatic leukodystrophy compared with nontransplanted control patients. JAMA Neurol. 2016;73(9):1133–40.Google Scholar

Ahrens-Nicklas, R, Schlotawa, L, Ballabio, A, et al. Complex care of individuals with multiple sulfatase deficiency: Clinical cases and consensus statement. Mol Genet Metab. 2018;123(3):337–46.Google Scholar

Brunetti-Pierri, N, Scaglia, F. GM1 gangliosidosis: Review of clinical, molecular, and therapeutic aspects. Mol Genet Metab. 2008;94(4):391–6.Google Scholar

Steenweg, ME, Vanderver, A, Blaser, S, et al. Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain. 2010;133(10):2971–82.Google Scholar

Roze, E, Paschke, E, Lopez, N, et al. Dystonia and parkinsonism in GM1 type 3 gangliosidosis. Mov Disord. 2005;20(10):1366–9.Google Scholar

Deodato, F, Procopio, E, Rampazzo, A, et al. The treatment of juvenile/adult GM1-gangliosidosis with miglustat may reverse disease progression. Metab Brain Dis. 2017;32(5):1529–36.Google Scholar

Smith, NJ, Winstone, AM, Stellitano, L, Cox, TM, Verity, CM. GM2 gangliosidosis in a UK study of children with progressive neurodegeneration: 73 cases reviewed. Dev Med Child Neurol. 2012;54(2):176–82.Google Scholar

Maegawa, GH, Stockley, T, Tropak, M, et al. The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported. Pediatrics. 2006;118(5):e1550-62.Google Scholar

Frey, LC, Ringel, SP, Filley, CM. The natural history of cognitive dysfunction in late-onset GM2 gangliosidosis. Arch Neurol. 2005;62(6):989–94.Google Scholar

Willems, PJ, Gatti, R, Darby, JK, et al. Fucosidosis revisited: A review of 77 patients. Am J Med Genet. 1991;38(1):111–31.Google Scholar

Moser, HW, Raymond, GV, Dubey, P. Adrenoleukodystrophy: New approaches to a neurodegenerative disease. JAMA. 2005;294(24):3131–4.Google Scholar

Loes, DJ, Fatemi, A, Melhem, ER, et al. Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy. Neurology. 2003;61(3):369–74.Google Scholar

Mahmood, A, Raymond, GV, Dubey, P, Peters, C, Moser, HW. Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: A comparison study. Lancet Neurol. 2007;6(8):687–92.Google Scholar

Engelen, M, Barbier, M, Dijkstra, IM, et al. X-linked adrenoleukodystrophy in women: A cross-sectional cohort study. Brain. 2014;137(Pt 3):693–706.Google Scholar

Steinberg, SJ, Dodt, G, Raymond, GV, et al. Peroxisome biogenesis disorders. Biochim Biophys Acta. 2006;1763(12):1733–48.Google Scholar

Ebberink, MS, Csanyi, B, Chong, WK, et al. Identification of an unusual variant peroxisome biogenesis disorder caused by mutations in the PEX16 gene. J Med Genet. 2010;47(9):608–15.Google Scholar

Patel, KP, O’Brien, TW, Subramony, SH, Shuster, J, Stacpoole, PW. The spectrum of pyruvate dehydrogenase complex deficiency: Clinical, biochemical and genetic features in 371 patients. Mol Genet Metab. 2012;106(3):385–94.Google Scholar

Cross, JH, Connelly, A, Gadian, DG, et al. Clinical diversity of pyruvate dehydrogenase deficiency. Pediatr Neurol. 1994;10(4):276–83.Google Scholar

Boczonadi, V, Jennings, MJ, Horvath, R. The role of tRNA synthetases in neurological and neuromuscular disorders. FEBS Lett. 2018;592(5):703–17.Google Scholar

Diodato, D, Ghezzi, D, Tiranti, V. The mitochondrial aminoacyl tRNA synthetases: Genes and syndromes. Int J Cell Biol. 2014;2014:787956.Google Scholar

Bayat, V, Thiffault, I, Jaiswal, M, et al. Mutations in the mitochondrial methionyl-tRNA synthetase cause a neurodegenerative phenotype in flies and a recessive ataxia (ARSAL) in humans. PLoS Biol. 2012;10(3):e1001288.Google Scholar

Matalon, RM, Michals-Matalon, K. Spongy degeneration of the brain, Canavan disease: Biochemical and molecular findings. Front Biosci. 2000;5:D307-11.Google Scholar

Hennermann, JB, Berger, JM, Grieben, U, Scharer, G, Van Hove, JL. Prediction of long-term outcome in glycine encephalopathy: A clinical survey. J Inherit Metab Dis. 2012;35(2):253–61.Google Scholar

Steiman, GS, Yudkoff, M, Berman, PH, Blazer-Yost, B, Segal, S. Late-onset nonketotic hyperglycinemia and spinocerebellar degeneration. J Pediatr. 1979;94(6):907–11.Google Scholar

Bank, WJ, Morrow, G, 3rd. A familial spinal cord disorder with hyperglycinemia. Arch Neurol. 1972;27(2):136–44.Google Scholar

Chiong, MA, Procopis, P, Carpenter, K, Wilcken, B. Late-onset nonketotic hyperglycinemia with leukodystrophy and an unusual clinical course. Pediatr Neurol. 2007;37(4):283–6.Google Scholar

van der Crabben, SN, Verhoeven-Duif, NM, Brilstra, EH, et al. An update on serine deficiency disorders. J Inherit Metab Dis. 2013;36(4):613–9.Google Scholar

de Koning, TJ, Jaeken, J, Pineda, M, et al. Hypomyelination and reversible white matter attenuation in 3-phosphoglycerate dehydrogenase deficiency. Neuropediatrics. 2000;31(6):287–92.Google Scholar

Ruzzo, EK, Capo-Chichi, JM, Ben-Zeev, B, et al. Deficiency of asparagine synthetase causes congenital microcephaly and a progressive form of encephalopathy. Neuron. 2013;80(2):429–41.Google Scholar

Alfadhel, M, Alrifai, MT, Trujillano, D, et al. Asparagine synthetase deficiency: New inborn errors of metabolism. JIMD Rep. 2015;22:11–6.Google Scholar

Fraser, JL, Venditti, CP. Methylmalonic and propionic acidemias: Clinical management update. Curr Opin Pediatr. 2016;28(6):682–93.Google Scholar

Cherin, P, Rose, C, de Roux-Serratrice, C, et al. The neurological manifestations of Gaucher disease type 1: The French Observatoire on Gaucher disease (FROG). J Inherit Metab Dis. 2010;33(4):331–8.Google Scholar

Mignot, C, Doummar, D, Maire, I, De Villemeur, TB, French Type 2 Gaucher Disease Study Group. Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev. 2006;28(1):39–48.Google Scholar

Roshan Lal, T, Sidransky, E. The spectrum of neurological manifestations associated with Gaucher disease. Diseases. 2017;5(1).Google Scholar

Nagappa, M, Bindu, PS, Taly, AB, Sinha, S. Oculomotor apraxia in Gaucher disease. Pediatr Neurol. 2015;52(4):468–9.Google Scholar

Perucca, G, Soares, BP, Stagliano, S, et al. Thalamic and dentate nucleus abnormalities in the brain of children with Gaucher disease. Neuroradiology. 2018;60(12):1353–6.Google Scholar

Weiss, K, Gonzalez, A, Lopez, G, et al. The clinical management of type 2 Gaucher disease. Mol Genet Metab. 2015;114(2):110–22.Google Scholar

Hogarth, P, Kurian, MA, Gregory, A, et al. Consensus clinical management guideline for pantothenate kinase-associated neurodegeneration (PKAN). Mol Genet Metab. 2017;120(3):278–87.Google Scholar

Illingworth, MA, Meyer, E, Chong, WK, et al. PLA2G6-associated neurodegeneration (PLAN): Further expansion of the clinical, radiological and mutation spectrum associated with infantile and atypical childhood-onset disease. Mol Genet Metab. 2014;112(2):183–9.Google Scholar

Fuijkschot, J, Theelen, T, Seyger, MM, van der Graaf, M, de Groot, IJ, Wevers, RA, et al. Sjögren–Larsson syndrome in clinical practice. J Inherit Metab Dis. 2012;35(6):955–62.Google Scholar

Caviness, JN, Alving, LI, Maraganore, DM, et al. The incidence and prevalence of myoclonus in Olmsted County, Minnesota. Mayo Clin Proc. 1999;74(6):565–9.Google Scholar

Gouider-Khouja, N, Kraoua, I, Benrhouma, H, Fraj, N, Rouissi, A. Movement disorders in neuro-metabolic diseases. Eur J Paediatr Neurol. 2010;14(4):304–7.Google Scholar

Zutt, R, van Egmond, ME, Elting, JW, et al. A novel diagnostic approach to patients with myoclonus. Nat Rev Neurol. 2015;11(12):687–97.Google Scholar

Apartis, E, Vercueil, L. To jerk or not to jerk: A clinical pathophysiology of myoclonus. Rev Neurol (Paris). 2016; 172 (8–9): 465–76.Google Scholar

Minassian, BA. The progressive myoclonus epilepsies. Prog Brain Res. 2014;213:113–22.Google Scholar

van der Veen, S, Zutt, R, Elting, JWJ, et al. Progressive myoclonus ataxia: Time for a new definition? Mov Disord. 2018;33(8):1281–6.Google Scholar

Caviness, JN. Treatment of myoclonus. Neurotherapeutics. 2014;11(1):188–200.Google Scholar

Koens, LH, Kuiper, A, Coenen, MA, et al. Ataxia, dystonia and myoclonus in adult patients with Niemann–Pick type C. Orphanet J Rare Dis. 2016;11:121.Google Scholar

Ritz, K, Gerrits, MC, Foncke, EM, et al. Myoclonus-dystonia: Clinical and genetic evaluation of a large cohort. J Neurol Neurosurg Psychiatry. 2009;80(6):653–8.Google Scholar

Dreissen, YE, Tijssen, MA. The startle syndromes: Physiology and treatment. Epilepsia. 2012;53 Suppl 7:3–11.Google Scholar

Neveling, K, Feenstra, I, Gilissen, C, et al. A post-hoc comparison of the utility of Sanger sequencing and exome sequencing for the diagnosis of heterogeneous diseases. Hum Mutat. 2013;34(12):1721–6.Google Scholar

van Egmond, ME, Lugtenberg, CHA, Brouwer, OF, et al. A post hoc study on gene panel analysis for the diagnosis of dystonia. Mov Disord. 2017;32(4):569–75.Google Scholar

Coutelier, M, Goizet, C, Durr, A, et al. Alteration of ornithine metabolism leads to dominant and recessive hereditary spastic paraplegia. Brain. 2015;138(Pt 8):2191–205.Google Scholar

Campistol, J. Epilepsy in inborn errors of metabolism with therapeutic options. Semin Pediatr Neurol. 2016;23(4):321–31.Google Scholar

Malek, N, Stewart, W, Greene, J. The progressive myoclonic epilepsies. Pract Neurol. 2015;15(3):164–71.Google Scholar

Sedel, F, Gourfinkel-An, I, Lyon-Caen, O, et al. Epilepsy and inborn errors of metabolism in adults: A diagnostic approach. J Inherit Metab Dis. 2007;30(6):846–54.Google Scholar

Beal, JC, Cherian, K, Moshe, SL. Early-onset epileptic encephalopathies: Ohtahara syndrome and early myoclonic encephalopathy. Pediatr Neurol. 2012;47(5):317–23.Google Scholar

Koens, LH, Tijssen, MAJ, Lange, F, et al. Eye movement disorders and neurological symptoms in late-onset inborn errors of metabolism. Mov Disord. 2018;33(12):1844–56.Google Scholar

Hollak, CEM, Lachman, R. Inherited Metabolic Disease in Adults: A Clinical Guide. New York, NY: Oxford University Press; 2016.Google Scholar

Sedel, F, Lyon-Caen, O, Saudubray, JM. Therapy insight: Inborn errors of metabolism in adult neurology. A clinical approach focused on treatable diseases. Nat Clin Pract Neurol. 2007;3(5):279–90.Google Scholar

Poll-The, BT, de Buy, Maillette Wenniger-Prick, LJ. The eye in metabolic diseases: Clues to diagnosis. Eur J Paediatr Neurol. 2011;15(3):197–204.Google Scholar

Poll-The, BT, de Buy, Maillette Wenniger-Prick, LJ, Barth, PG, Duran, M. The eye as a window to inborn errors of metabolism. J Inherit Metab Dis. 2003; 26 (2–3): 229–44.Google Scholar

Schultz, M L, Tecedor, L, Chang, M, Davidson, BL. Clarifying lysosomal storage diseases. Trends Neurosci. 2011;34(8):401–10.Google Scholar

Accardo, A, Pensiero, S, Ciana, G, Parentin, F, Bembi, B. Eye movement impairment recovery in a Gaucher patient treated with miglustat. Neurol Res Int. 2010;2010:358534.Google Scholar

Park, JK, Orvisky, E, Tayebi, N, et al. Myoclonic epilepsy in Gaucher disease: Genotype–phenotype insights from a rare patient subgroup. Pediatr Res. 2003;53(3):387–95.Google Scholar

Stelten, BML, van de Warrenburg, BPC, Wevers, RA, Verrips, A. Movement disorders in cerebrotendinous xanthomatosis. Parkinsonism Relat Disord. 2019;58:12–6.Google Scholar

Van Hove, J, Coughlin, C, II, Scharer, G. Glycine encephalopathy. GeneReviews®. 2002;Nov 14 (updated Jul 11, 2013).Google Scholar

Wang, D, Pascual, JM, De Vivo, D. Transporter type 1 deficiency syndrome. GeneReviews®. 2002;Jul 30 (updated Mar 1, 2018 ).Google Scholar

Toelle, SP, Wille, D, Schmitt, B, et al. Sensory stimulus-sensitive drop attacks and basal ganglia calcification: New findings in a patient with FOLR1 deficiency. Epileptic Disord. 2014;16(1):88–92.Google Scholar

Mastrangelo, M. Actual insights into treatable inborn errors of metabolism causing epilepsy. J Pediatr Neurosci. 2018;13(1):13–23.Google Scholar

Desai, S, Ganesan, K, Hegde, A. Biotinidase deficiency: A reversible metabolic encephalopathy. Neuroimaging and MR spectroscopic findings in a series of four patients. Pediatr Radiol. 2008;38(8):848–56.Google Scholar

Bahi-Buisson, N, Kaminska, A, Nabbout, R, et al. Epilepsy in Menkes disease: Analysis of clinical stages. Epilepsia. 2006;47(2):380–6.Google Scholar

Demarquay, G, Setiey, A, Morel, Y, et al. Clinical report of three patients with hereditary hemochromatosis and movement disorders. Mov Disord. 2000;15(6):1204–9.Google Scholar

Veerapandiyan, A, Winchester, SA, Gallentine, WB, et al. Electroencephalographic and seizure manifestations of pyridoxal 5’-phosphate-dependent epilepsy. Epilepsy Behav. 2011;20(3):494–501.Google Scholar

Brautigam, C, Hyland, K, Wevers, R, et al. Clinical and laboratory findings in twins with neonatal epileptic encephalopathy mimicking aromatic L-amino acid decarboxylase deficiency. Neuropediatrics. 2002;33(3):113–7.Google Scholar

Stamelou, M, Mencacci, NE, Cordivari, C, et al. Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency. Neurology. 2012;79(5):435–41.Google Scholar

Mancuso, M, Orsucci, D, Angelini, C, et al. Myoclonus in mitochondrial disorders. Mov Disord. 2014;29(6):722–8.Google Scholar

Cohen, BH, Chinnery, PF, Copeland, WC. POLG-related disorders. GeneReviews®. 2010;Mar 16 (updated Mar 1, 2018).Google Scholar

Salviati, L, Trevisson, E, Doimo, M, Navas, P. Primary coenzyme Q10 deficiency. GeneReviews®. 2017;Jan 26.Google Scholar

Walker, MA, Mohler, KP, Hopkins, KW, et al. Novel compound heterozygous mutations expand the recognized phenotypes of FARS2-linked disease. J Child Neurol. 2016;31(9):1127–37.Google Scholar

Coughlin, CR, 2nd, Scharer, GH, Friederich, MW, et al. Mutations in the mitochondrial cysteinyl-tRNA synthase gene, CARS2, lead to a severe epileptic encephalopathy and complex movement disorder. J Med Genet. 2015;52(8):532–40.Google Scholar

Schultz, A, Ajavi, T, Specchio, N, et al. Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med. 2018;378:1898–907.Google Scholar

Kim, J, Hu, C, Moufawad El Achkar, C, et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N Engl J Med. 2019;381:1644–52.Google Scholar

Monbaliu, E, De Cock, P, Mailleux, L, Dan, B, Feys, H. The relationship of dystonia and choreoathetosis with activity, participation and quality of life in children and youth with dyskinetic cerebral palsy. Eur J Paediatr Neurol. 2017;21(2):327–35.Google Scholar

Eggink, H, Kuiper, A, Peall, KJ, et al. Rare inborn errors of metabolism with movement disorders: A case study to evaluate the impact upon quality of life and adaptive functioning. Orphanet J Rare Dis. 2014;9:177.Google Scholar

Dijk, JM, Tijssen, MA. Management of patients with myoclonus: Available therapies and the need for an evidence-based approach. Lancet Neurol. 2010;9(10):1028–36.Google Scholar

Book contents

Section I - General Principles and a Phenomenology-Based Approach to Movement Disorders and Inherited Metabolic Disorders

Summary

Access options

References

References

References

References

References

References

References

References

References

References

References

References

Book contents

Section I - General Principles and a Phenomenology-Based Approach to Movement Disorders and Inherited Metabolic Disorders

Summary

Access options

References

References

References

References

References

References

References

References

References

References

References

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive